Gene	Gene synonym	Ensembl	Gene description	Chromosome	Position	Protein class	Evidence	Antibody	Reliability (IH)	Reliability (Mouse Brain)	Reliability (IF)	Subcellular location	Prognostic p-value	RNA cancer category	RNA tissue category	RNA TS	RNA TS TPM	TPM max in non-specific	RNA cell line category	RNA CS	RNA CS TPM
ABI1	ABI-1, E3B1, SSH3BP1	ENSG00000136754	Abl interactor 1	10	26746593-26861087	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB008375, HPA029973, HPA068407	Approved		Supported	Plasma membrane<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 87.4	Expressed in all		
ABL1	ABL, c-ABL, JTK7, p150	ENSG00000097007	ABL proto-oncogene 1, non-receptor tyrosine kinase	9	130713946-130887675	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002686, HPA027251, HPA027280, HPA028409	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 83.9	Expressed in all		
ABL2	ABLL, ARG	ENSG00000143322	ABL proto-oncogene 2, non-receptor tyrosine kinase	1	179099327-179229684	Cancer-related genes, Enzymes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001866, CAB017106, HPA072754	Uncertain		Supported	Nucleoplasm	Renal cancer:1.78e-7 (unfavourable), Cervical cancer:3.50e-4 (unfavourable), Urothelial cancer:8.40e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 20.3	Expressed in all		
ACKR3	CMKOR1, CXCR7, GPR159, RDC1	ENSG00000144476	Atypical chemokine receptor 3	2	236567787-236582358	Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins	Evidence at protein level	HPA032003, HPA049718	Approved		Supported	Vesicles<br>Plasma membrane	Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 176.7	Cell line enhanced		RT4: 248.8;SiHa: 100.8;U-2197: 297.4
ACSL3	ACS3, FACL3, PRO2194	ENSG00000123983	Acyl-CoA synthetase long-chain family member 3	2	222860934-222944639	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA011315, HPA071021	Uncertain		Approved	Nucleoli<br>Lipid droplets	Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 682.1	Expressed in all		
ACSL6	ACS2, FACL6, KIAA0837, LACS2, LACS5	ENSG00000164398	Acyl-CoA synthetase long-chain family member 6	5	131949973-132012243	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA040470	Enhanced					Group enriched	Group enriched	6	bone marrow: 18.0;cerebral cortex: 61.9;parathyroid gland: 22.5;seminal vesicle: 29.0;testis: 51.4	adrenal gland: 6.4	Group enriched	6	SCLC-21H: 13.0;U-937: 5.2
ACVR1	ACVR1A, ACVRLK2, ALK2, SKR1	ENSG00000115170	Activin A receptor type 1	2	157736444-157875862	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA007505, HPA046514	Approved		Approved	Nucleoli<br>Cytosol	Urothelial cancer:5.17e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 74.2	Mixed		
ACVR2A	ACTRII, ACVR2	ENSG00000121989	Activin A receptor type 2A	2	147844517-147930826	Cancer-related genes, Enzymes, Predicted membrane proteins	Evidence at protein level	HPA046997	Approved		Approved	Cytosol	Renal cancer:1.62e-4 (favourable)	Expressed in all	Mixed			skin: 22.5	Mixed		
AFDN	AF-6, AF6, MLLT4	ENSG00000130396	Afadin, adherens junction formation factor	6	167826922-167972023	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB013496, HPA030212, HPA030213, HPA030214, HPA030215, HPA049868	Approved		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cell Junctions	Breast cancer:7.43e-5 (unfavourable)	Expressed in all	Expressed in all			esophagus: 110.7	Mixed		
AFF1	AF-4, AF4, MLLT2, PBM1	ENSG00000172493	AF4/FMR2 family member 1	4	86935002-87141054	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA069947			Approved	Nucleoplasm<br>Mitochondria		Expressed in all	Expressed in all			thyroid gland: 91.6	Expressed in all		
AFF3	LAF4, MLLT2-like	ENSG00000144218	AF4/FMR2 family member 3	2	99545419-100142739	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA044512, HPA053379	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:5.64e-4 (unfavourable)	Tissue enhanced	Mixed			prostate: 29.7	Cell line enhanced		Daudi: 35.6;U-698: 50.7
AFF4	AF5Q31, MCEF	ENSG00000072364	AF4/FMR2 family member 4	5	132875379-132963634	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023690, HPA029634	Approved		Supported	Nucleus<br>Nucleoli fibrillar center	Thyroid cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 74.2	Expressed in all		
AKAP9	AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO	ENSG00000127914	A-kinase anchoring protein 9	7	91940867-92110673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA008548, CAB012909, HPA026109	Enhanced		Enhanced	Golgi apparatus<br>Vesicles<br>Centrosome	Renal cancer:2.10e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 37.8	Expressed in all		
AKT1	AKT, PKB, PRKBA, RAC	ENSG00000142208	AKT serine/threonine kinase 1	14	104769349-104795751	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002891, CAB003765	Enhanced		Supported	Nucleus<br>Microtubules	Renal cancer:2.12e-4 (favourable), Ovarian cancer:4.83e-4 (favourable)	Expressed in all	Expressed in all			prostate: 106.4	Expressed in all		
AKT2		ENSG00000105221	AKT serine/threonine kinase 2	19	40230317-40285536	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004204, HPA064521	Uncertain		Supported	Nucleus<br>Vesicles<br>Cytosol	Endometrial cancer:1.05e-6 (unfavourable), Prostate cancer:4.74e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 170.1	Expressed in all		
ALDH2		ENSG00000111275	Aldehyde dehydrogenase 2 family (mitochondrial)	12	111766887-111817529	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA051065	Approved				Liver cancer:3.95e-7 (favourable), Renal cancer:5.24e-6 (favourable), Endometrial cancer:2.63e-4 (favourable), Urothelial cancer:7.71e-4 (unfavourable)	Expressed in all	Expressed in all			liver: 441.5	Cell line enhanced		HHSteC: 81.5;SK-BR-3: 150.4
ALK	CD246	ENSG00000171094	Anaplastic lymphoma receptor tyrosine kinase	2	29192774-29921566	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010694	Approved		Supported	Plasma membrane		Group enriched	Tissue enhanced		cerebral cortex: 2.7;testis: 2.0	adrenal gland: 0.5	Cell line enriched	6	SH-SY5Y: 28.3
AMER1	FAM123B, FLJ39827, RP11-403E24.2, WTX	ENSG00000184675	APC membrane recruitment protein 1	X	64185117-64205744	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA065214, HPA065265	Approved		Supported	Nuclear bodies<br>Vesicles<br>Plasma membrane		Expressed in all	Mixed			ovary: 7.7	Mixed		
APC	DP2, DP2.5, DP3, PPP1R46	ENSG00000134982	APC, WNT signaling pathway regulator	5	112707498-112846239	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA013349	Supported					Expressed in all	Tissue enhanced		cerebral cortex: 60.1	parathyroid gland: 19.9	Expressed in all		
AR	AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1	ENSG00000169083	Androgen receptor	X	67544032-67730619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000001, HPA065701, CAB065764	Enhanced		Approved	Mitochondria	Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable)	Mixed	Mixed			fallopian tube: 42.3	Cell line enhanced		AF22: 15.6;HAP1: 21.1;LHCN-M2: 14.9;RH-30: 28.3
ARHGAP26	GRAF, KIAA0621, OPHN1L, OPHN1L1	ENSG00000145819	Rho GTPase activating protein 26	5	142770384-143229011	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA035106, HPA035107	Enhanced		Approved	Cytosol	Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable)	Expressed in all	Mixed			cerebral cortex: 30.8	Cell line enhanced		Karpas-707: 61.5
ARHGEF12	KIAA0382, LARG	ENSG00000196914	Rho guanine nucleotide exchange factor 12	11	120336914-120489936	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA018911, CAB025581	Approved		Approved	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:5.43e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 145.8	Mixed		
ARID1A	B120, BAF250, BAF250a, C10rf4, C1orf4, P270, SMARCF1	ENSG00000117713	AT-rich interaction domain 1A	1	26693236-26782104	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005456, CAB016334	Supported		Enhanced	Nucleoplasm	Liver cancer:4.18e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
ARID1B	6A3-5, BAF250b, DAN15, ELD/OSA1, KIAA1235, p250R	ENSG00000049618	AT-rich interaction domain 1B	6	156777374-157210779	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA016511, HPA075291	Approved		Supported	Nucleoplasm	Breast cancer:1.04e-4 (unfavourable), Ovarian cancer:4.16e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 71.2	Expressed in all		
ARID2	BAF200, DKFZp686G052, FLJ30619, KIAA1557	ENSG00000189079	AT-rich interaction domain 2	12	45729665-45908040	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063044			Supported	Nucleoplasm<br>Plasma membrane	Head and neck cancer:5.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 47.3	Expressed in all		
ARNT	bHLHe2, HIF-1beta	ENSG00000143437	Aryl hydrocarbon receptor nuclear translocator	1	150809705-150876768	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001759, CAB004318	Enhanced		Supported	Nucleus<br>Nuclear bodies		Expressed in all	Expressed in all			ovary: 46.7	Cell line enriched	7	U-698: 274.9
ASPSCR1	ASPL, ASPS, TUG, UBXD9, UBXN9	ENSG00000169696	ASPSCR1, UBX domain containing tether for SLC2A4	17	81976807-82017406	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026749	Approved		Supported	Nucleoplasm<br>Vesicles<br>Plasma membrane	Renal cancer:1.26e-4 (unfavourable), Pancreatic cancer:2.67e-4 (favourable), Head and neck cancer:8.55e-4 (favourable)	Expressed in all	Expressed in all			testis: 21.3	Expressed in all		
ASXL1	KIAA0978	ENSG00000171456	Additional sex combs like 1, transcriptional regulator	20	32358344-32439319	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA064156			Approved	Nucleus<br>Nucleoli	Endometrial cancer:2.86e-4 (unfavourable), Head and neck cancer:9.16e-4 (favourable)	Expressed in all	Expressed in all			testis: 68.5	Expressed in all		
ATF1	TREB36	ENSG00000123268	Activating transcription factor 1	12	50763710-50821122	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016222, HPA055069, HPA055406	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.53e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 39.6	Expressed in all		
ATIC	AICARFT, IMPCHASE, PURH	ENSG00000138363	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	2	215311817-215349773	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013462, HPA021012	Supported		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:1.99e-7 (unfavourable), Renal cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 44.8	Expressed in all		
ATM	ATA, ATC, ATD, ATDC, TEL1, TELO1	ENSG00000149311	ATM serine/threonine kinase	11	108222484-108369102	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000102, HPA067142	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 40.8	Expressed in all		
ATP1A1		ENSG00000163399	ATPase Na+/K+ transporting subunit alpha 1	1	116372668-116410261	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB018702, CAB069993	Enhanced				Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 2487.1	Expressed in all		
ATP2B3	CFAP39, CLA2, PMCA3, SCAX1	ENSG00000067842	ATPase plasma membrane Ca2+ transporting 3	X	153517676-153582939	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA001583	Enhanced		Uncertain	Golgi apparatus<br>Plasma membrane		Not detected	Group enriched	8	adrenal gland: 12.1;cerebral cortex: 19.0	fallopian tube: 2.0	Cell line enhanced		SCLC-21H: 11.7;SH-SY5Y: 3.1;THP-1: 1.7;U-937: 1.9
ATR	FRP1, MEC1, SCKL, SCKL1	ENSG00000175054	ATR serine/threonine kinase	3	142449235-142578826	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054320			Supported	Nucleoplasm<br>Golgi apparatus	Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 15.4	Expressed in all		
ATRX	JMS, MRX52, RAD54, XH2, XNP	ENSG00000085224	ATRX, chromatin remodeler	X	77504878-77786269	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001906, CAB009372, HPA064684, CAB068176	Supported		Supported	Nuclear bodies		Expressed in all	Expressed in all			parathyroid gland: 54.4	Expressed in all		
AXIN1	PPP1R49	ENSG00000103126	Axin 1	16	287440-352673	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012987	Approved		Supported	Nucleoli<br>Vesicles	Liver cancer:3.38e-5 (unfavourable)	Expressed in all	Expressed in all			spleen: 15.5	Expressed in all		
AXIN2	DKFZp781B0869, MGC126582	ENSG00000168646	Axin 2	17	65528563-65561647	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB012283, CAB017783	Approved		Uncertain	Nucleus<br>Plasma membrane<br>Cytosol	Pancreatic cancer:6.58e-4 (favourable)	Expressed in all	Mixed			endometrium: 31.1	Cell line enhanced		AF22: 26.9;CACO-2: 43.2;Hep G2: 53.5
BAP1	hucep-6, KIAA0272, UCHL2	ENSG00000163930	BRCA1 associated protein 1	3	52401013-52410350	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004322, HPA028814, HPA028815, HPA055560	Approved		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:3.29e-7 (favourable)	Expressed in all	Expressed in all			testis: 118.2	Expressed in all		
BCL10	c-E10, CARMEN, CIPER, CLAP, mE10	ENSG00000142867	B-cell CLL/lymphoma 10	1	85266248-85277090	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB001944, HPA017925	Approved		Approved	Nucleoplasm	Liver cancer:7.21e-7 (unfavourable), Colorectal cancer:2.51e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 30.5	Expressed in all		
BCL11A	BCL11A-L, BCL11A-S, BCL11A-XL, CTIP1, EVI9, HBFQTL5, ZNF856	ENSG00000119866	B-cell CLL/lymphoma 11A	2	60451167-60553567	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB014891, HPA029003	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies		Mixed	Tissue enhanced		skin: 41.0	tonsil: 30.6	Cell line enhanced		Daudi: 24.7;MOLT-4: 28.5;REH: 32.5;U-698: 43.2
BCL11B	CTIP-2, CTIP2, hRIT1-alpha, ZNF856B	ENSG00000127152	B-cell CLL/lymphoma 11B	14	99169287-99271524	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049117	Enhanced	Supported	Approved	Nucleus<br>Nucleoli fibrillar center	Urothelial cancer:7.48e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 12.2;skin: 18.7	tonsil: 7.4	Cell line enriched	6	MOLT-4: 41.1
BCL2	Bcl-2, PPP1R50	ENSG00000171791	BCL2, apoptosis regulator	18	63123346-63320128	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000003, HPA055295	Enhanced		Supported	Nucleoplasm<br>Nuclear membrane	Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable)	Expressed in all	Tissue enhanced		thyroid gland: 69.3	parathyroid gland: 35.3	Cell line enhanced		Karpas-707: 59.5;U-266/70: 217.8
BCL3	BCL4, D19S37	ENSG00000069399	B-cell CLL/lymphoma 3	19	44747705-44760044	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002051, HPA047514	Approved		Supported	Nucleoplasm<br>Vesicles<br>Midbody	Renal cancer:3.13e-14 (unfavourable), Melanoma:3.74e-4 (favourable), Glioma:5.58e-4 (unfavourable), Breast cancer:9.67e-4 (favourable)	Expressed in all	Expressed in all			appendix: 30.1	Cell line enhanced		HDLM-2: 55.4;SiHa: 65.8
BCL6	BCL5, BCL6A, LAZ3, ZBTB27, ZNF51	ENSG00000113916	B-cell CLL/lymphoma 6	3	187721377-187745727	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000307, HPA004899, HPA050645	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus	Renal cancer:1.27e-9 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 113.5	Cell line enhanced		Daudi: 112.8;U-698: 150.4
BCL7A	BCL7	ENSG00000110987	BCL tumor suppressor 7A	12	122019422-122062044	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019762	Approved		Approved	Nucleoplasm<br>Vesicles	Renal cancer:1.54e-6 (favourable), Liver cancer:2.04e-4 (unfavourable), Colorectal cancer:6.81e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 13.8	Cell line enhanced		Daudi: 37.3;U-698: 41.3
BCL9		ENSG00000116128	B-cell CLL/lymphoma 9	1	147541412-147626216	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020274	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies	Liver cancer:6.74e-4 (unfavourable)	Expressed in all	Mixed			fallopian tube: 26.5	Cell line enhanced		NTERA-2: 42.4
BCL9L	DLNB11	ENSG00000186174	B-cell CLL/lymphoma 9-like	11	118893875-118925608	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA049370, HPA053421	Uncertain		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 35.0	Mixed		
BCOR	FLJ20285, KIAA1575	ENSG00000183337	BCL6 corepressor	X	40049815-40177329	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA056308, HPA073591			Enhanced	Nucleus	Liver cancer:1.30e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 34.0	Expressed in all		
BCORL1	CXorf10, FLJ11362	ENSG00000085185	BCL6 corepressor-like 1	X	129981107-130058083	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA031775, HPA031777, HPA068568	Uncertain		Approved	Nucleoplasm<br>Plasma membrane	Endometrial cancer:2.20e-5 (unfavourable), Renal cancer:5.00e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 18.3	Cell line enhanced		HAP1: 51.8
BCR	ALL, BCR1, CML, D22S11, D22S662, PHL	ENSG00000186716	BCR, RhoGEF and GTPase activating protein	22	23179704-23318037	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB010421, CAB018545, HPA038337	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:9.15e-10 (favourable)	Expressed in all	Mixed			cerebral cortex: 47.0	Expressed in all		
BIRC3	API2, c-IAP2, cIAP2, hiap-1, MALT2, MIHC, RNF49	ENSG00000023445	Baculoviral IAP repeat containing 3	11	102317450-102339403	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002317	Enhanced	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:6.66e-6 (unfavourable), Pancreatic cancer:3.03e-4 (unfavourable), Breast cancer:3.60e-4 (favourable), Colorectal cancer:9.35e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 138.1	appendix: 117.5	Cell line enhanced		CAPAN-2: 106.1;Daudi: 77.5;HDLM-2: 96.2;hTERT-HME1: 79.1
BRAF	BRAF1	ENSG00000157764	B-Raf proto-oncogene, serine/threonine kinase	7	140719327-140924764	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001328, CAB004552, HPA071048	Approved		Approved	Vesicles<br>Cytosol		Expressed in all	Expressed in all			testis: 41.8	Expressed in all		
BRCA1	BRCC1, FANCS, PPP1R53, RNF53	ENSG00000012048	BRCA1, DNA repair associated	17	43044295-43170245	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB001946, HPA034966, HPA057371	Enhanced					Expressed in all	Mixed			testis: 23.9	Expressed in all		
BRCA2	BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11	ENSG00000139618	BRCA2, DNA repair associated	13	32315474-32400266	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA026815	Uncertain		Approved	Nucleoplasm<br>Cytosol		Mixed	Tissue enhanced		testis: 5.2	bone marrow: 4.1	Mixed		
BRD3	KIAA0043, ORFX, RING3L	ENSG00000169925	Bromodomain containing 3	9	134030305-134068535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051830	Approved		Approved	Nuclear bodies	Renal cancer:2.71e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 19.6	Expressed in all		
BRD4	CAP, HUNK1, HUNKI, MCAP	ENSG00000141867	Bromodomain containing 4	19	15235519-15332545	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA015055, HPA061646, CAB068177, CAB068178	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			placenta: 41.9	Expressed in all		
BTG1	APRO2	ENSG00000133639	BTG anti-proliferation factor 1	12	92140278-92145897	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005972			Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.95e-7 (unfavourable), Breast cancer:4.36e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 261.0	Expressed in all		
BTK	AGMX1, ATK, IMD1, PSCTK1, XLA	ENSG00000010671	Bruton tyrosine kinase	X	101349447-101390796	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001198, HPA002028, CAB016689	Enhanced		Supported	Vesicles		Expressed in all	Tissue enhanced		lymph node: 65.2;tonsil: 70.8	spleen: 52.7	Cell line enhanced		Daudi: 147.2;HEL: 256.7;HMC-1: 868.2
C15orf65	FLJ27352	ENSG00000261652	Chromosome 15 open reading frame 65	15	55408548-55418764	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA067189	Approved		Approved	Nucleus<br>Cytosol	Endometrial cancer:3.18e-7 (favourable)	Expressed in all	Mixed			testis: 16.9	Mixed		
CACNA1D	CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2	ENSG00000157388	Calcium voltage-gated channel subunit alpha1 D	3	53328963-53813733	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels	Evidence at protein level	HPA020215	Uncertain		Approved	Nuclear membrane	Renal cancer:8.34e-8 (favourable)	Mixed	Mixed			fallopian tube: 13.5	Cell line enhanced		HMC-1: 19.6;RPMI-8226: 38.4;SK-BR-3: 7.4
CALR	cC1qR, CRT, FLJ26680, RO, SSA	ENSG00000179218	Calreticulin	19	12938578-12944489	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB001513, HPA002242, CAB019952	Enhanced				Renal cancer:1.11e-16 (unfavourable), Ovarian cancer:1.10e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1652.0	Expressed in all		
CAMTA1	KIAA0833	ENSG00000171735	Calmodulin binding transcription activator 1	1	6785324-7769706	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036342, HPA036343	Approved		Supported	Nucleoli<br>Cytosol	Ovarian cancer:4.10e-4 (favourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 99.9	Expressed in all		
CANT1	SCAN-1, SHAPY	ENSG00000171302	Calcium activated nucleotidase 1	17	78991717-79009867	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA019627, HPA019639, HPA022818	Enhanced				Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 115.7	Expressed in all		
CARD11	BIMP3, CARMA1	ENSG00000198286	Caspase recruitment domain family member 11	7	2906141-3043945	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA052984	Approved				Renal cancer:6.68e-8 (unfavourable), Urothelial cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 54.4;spleen: 40.2	appendix: 28.3	Cell line enhanced		Daudi: 86.5;RT4: 71.8;U-698: 73.9
CARS	CARS1	ENSG00000110619	Cysteinyl-tRNA synthetase	11	3000922-3057613	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002383, HPA002384, CAB075734, CAB075735, CAB075736, CAB075737	Enhanced		Enhanced	Cytosol	Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.16e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 28.2	Mixed		
CASP8	Casp-8, FLICE, MACH, MCH5	ENSG00000064012	Caspase 8	2	201233443-201287711	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001302, CAB002047, HPA005688, HPA006191	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.27e-6 (unfavourable), Ovarian cancer:1.25e-4 (favourable), Liver cancer:3.02e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 44.8	Expressed in all		
CBFA2T3	ETO2, MTG16, MTGR2, RUNX1T3, ZMYND4	ENSG00000129993	CBFA2/RUNX1 translocation partner 3	16	88874858-88977204	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA059931, HPA062423, HPA065890	Approved		Enhanced	Nucleoplasm	Head and neck cancer:3.95e-4 (favourable)	Mixed	Tissue enhanced		spleen: 18.7	lymph node: 10.4	Cell line enhanced		HEL: 57.7;K-562: 102.3;MOLT-4: 46.5;REH: 103.4;T-47d: 47.0
CBFB	PEBP2B	ENSG00000067955	Core-binding factor beta subunit	16	67029116-67101058	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA038852	Uncertain		Approved	Nucleus<br>Cytosol	Renal cancer:2.89e-8 (unfavourable), Liver cancer:2.83e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 97.5	Expressed in all		
CBL	c-Cbl, CBL2, RNF55	ENSG00000110395	Cbl proto-oncogene	11	119206276-119313926	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004350, HPA027956	Enhanced		Supported	Cytosol		Expressed in all	Mixed			testis: 33.9	Expressed in all		
CBLB	Cbl-b, RNF56	ENSG00000114423	Cbl proto-oncogene B	3	105655461-105869552	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA018327, HPA019880	Approved		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			lymph node: 28.0	Cell line enhanced		U-138 MG: 63.4
CBLC	CBL-3, CBL-SL, RNF57	ENSG00000142273	Cbl proto-oncogene C	19	44777869-44800634	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB008087, HPA035266	Approved		Approved	Nucleoplasm	Renal cancer:3.11e-6 (favourable)	Mixed	Tissue enhanced		duodenum: 52.5;skin: 41.9;small intestine: 44.0	colon: 21.4	Cell line enhanced		A-431: 38.2;BEWO: 28.0;CACO-2: 23.9;CAPAN-2: 51.1;HaCaT: 37.6;HBEC3-KT: 25.9;RT4: 29.6;SK-BR-3: 24.0
CCDC6	D10S170, H4, PTC, TPC, TST1	ENSG00000108091	Coiled-coil domain containing 6	10	59788763-59906656	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019049, HPA019051	Enhanced		Supported	Cytosol	Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.95e-4 (unfavourable), Head and neck cancer:5.48e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 44.4	Expressed in all		
CCNB1IP1	C14orf18, HEI10	ENSG00000100814	Cyclin B1 interacting protein 1	14	20311368-20333312	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level						Renal cancer:5.18e-6 (favourable)	Expressed in all	Expressed in all			ovary: 120.9	Expressed in all		
CCND1	BCL1, D11S287E, PRAD1, U21B31	ENSG00000110092	Cyclin D1	11	69641087-69654474	Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000024, HPA027802	Uncertain		Supported	Nucleoplasm	Pancreatic cancer:1.96e-4 (unfavourable), Head and neck cancer:5.51e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 340.4	skin: 140.5	Cell line enhanced		WM-115: 1198.2
CCND2		ENSG00000118971	Cyclin D2	12	4273772-4305350	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049138, HPA054196	Approved		Supported	Nucleoplasm	Thyroid cancer:9.76e-5 (favourable), Pancreatic cancer:2.52e-4 (favourable)	Expressed in all	Mixed			epididymis: 55.9	Cell line enhanced		AF22: 155.7;HDLM-2: 235.1;Karpas-707: 252.4;RH-30: 221.5
CCND3		ENSG00000112576	Cyclin D3	6	41934933-42050357	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000116	Approved				Thyroid cancer:8.08e-6 (favourable)	Expressed in all	Expressed in all			lymph node: 159.2	Expressed in all		
CCNE1	CCNE	ENSG00000105173	Cyclin E1	19	29811898-29824308	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB000308, CAB016682, HPA018169	Approved		Enhanced	Nucleoplasm	Endometrial cancer:6.35e-6 (unfavourable), Liver cancer:3.89e-5 (unfavourable), Ovarian cancer:2.97e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 44.6	testis: 22.5	Expressed in all		
CD274	B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1	ENSG00000120217	CD274 molecule	9	5450503-5470566	Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB030018, CAB076385	Enhanced		Approved	Cytosol	Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable)	Mixed	Mixed			appendix: 14.0	Cell line enhanced		HDLM-2: 82.8;HHSteC: 46.6;U-251 MG: 80.8
CD74	DHLAG	ENSG00000019582	CD74 molecule	5	150401637-150412929	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	CAB002506, HPA010592	Enhanced		Supported	Golgi apparatus	Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable)	Expressed in all	Expressed in all			spleen: 6545.9	Cell line enhanced		CAPAN-2: 1796.9;Daudi: 2297.1;HDLM-2: 4315.9;REH: 2549.8
CD79A	IGA, MB-1	ENSG00000105369	CD79a molecule	19	41877120-41881372	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000019	Enhanced				Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable)	Mixed	Group enriched	6	appendix: 263.8;lymph node: 515.1;spleen: 317.9;tonsil: 423.1	stomach: 63.3	Group enriched	23	Daudi: 1084.6;REH: 432.6;U-698: 905.8
CD79B	B29, IGB	ENSG00000007312	CD79b molecule	17	63928740-63932354	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA009178, CAB009751	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane<br>Cytosol	Head and neck cancer:2.35e-4 (favourable)	Expressed in all	Group enriched	5	appendix: 91.1;lymph node: 311.5;spleen: 157.4;tonsil: 189.1	bone marrow: 36.1	Group enriched	17	Daudi: 751.6;REH: 317.0;U-698: 986.5
CDC73	C1orf28, FIHP, HRPT1, HRPT2, parafibromin	ENSG00000134371	Cell division cycle 73	1	193122017-193253901	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016359, HPA030772	Enhanced		Supported	Nucleus<br>Cytosol		Expressed in all	Expressed in all			thyroid gland: 32.2	Expressed in all		
CDH1	CD324, UVO, uvomorulin	ENSG00000039068	Cadherin 1	16	68737225-68835548	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857	Enhanced		Supported	Golgi apparatus<br>Plasma membrane<br>Cell Junctions	Renal cancer:2.06e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 475.1	thyroid gland: 266.2	Cell line enhanced		BEWO: 645.6;CAPAN-2: 281.0;HaCaT: 273.9
CDH11	CAD11, OB	ENSG00000140937	Cadherin 11	16	64943753-65126112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB013072	Enhanced				Renal cancer:2.48e-9 (unfavourable)	Expressed in all	Tissue enhanced		ovary: 223.4	placenta: 173.7	Cell line enhanced		BJ: 205.7;fHDF/TERT166: 259.6;HSkMC: 159.5;PC-3: 262.9;U-2197: 178.5
CDK12	CRK7, CRKR, CRKRS, KIAA0904	ENSG00000167258	Cyclin dependent kinase 12	17	39461511-39564907	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA008038	Supported		Supported	Nucleus		Expressed in all	Expressed in all			testis: 33.8	Expressed in all		
CDK6	PLSTIRE	ENSG00000105810	Cyclin dependent kinase 6	7	92604921-92836594	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002637, CAB004363	Enhanced		Supported	Nucleoplasm<br>Cytosol	Pancreatic cancer:3.86e-6 (unfavourable), Urothelial cancer:2.33e-5 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 34.2	Cell line enhanced		MOLT-4: 366.7;REH: 201.1
CDKN1B	KIP1, P27KIP1	ENSG00000111276	Cyclin dependent kinase inhibitor 1B	12	12715058-12722371	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB003691, CAB021888, HPA059086	Approved		Supported	Nucleus<br>Vesicles	Liver cancer:3.25e-4 (unfavourable), Colorectal cancer:5.15e-4 (favourable), Renal cancer:8.39e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 73.1	Mixed		
CDKN2A	ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf	ENSG00000147889	Cyclin dependent kinase inhibitor 2A	9	21967753-21995301	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB000093, CAB000445, CAB018232, HPA047838	Uncertain		Enhanced	Nucleoli	Endometrial cancer:1.82e-7 (unfavourable), Renal cancer:5.76e-7 (unfavourable), Liver cancer:2.17e-4 (unfavourable), Head and neck cancer:5.19e-4 (favourable)	Expressed in all	Mixed			parathyroid gland: 7.5	Cell line enhanced		HEK93: 297.6
CDKN2C	INK4C, p18	ENSG00000123080	Cyclin dependent kinase inhibitor 2C	1	50960745-50974633	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005303, CAB018398, HPA019057, HPA019764	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.70e-10 (unfavourable), Liver cancer:1.58e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 80.3	Mixed		
CDX2	CDX3	ENSG00000165556	Caudal type homeobox 2	13	27962137-27971139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002221, HPA045669, HPA049580	Enhanced		Supported	Nucleoplasm		Tissue enriched	Group enriched	6	colon: 30.8;duodenum: 22.3;rectum: 24.9;small intestine: 30.2	appendix: 4.7	Cell line enhanced		CACO-2: 9.4;CAPAN-2: 3.3;HEK93: 5.6
CEBPA	C/EBP-alpha, CEBP	ENSG00000245848	CCAAT/enhancer binding protein alpha	19	33299934-33302564	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA052734, HPA065037, HPA067937	Approved		Approved	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			adipose tissue: 108.0	Cell line enhanced		BEWO: 187.4;THP-1: 270.7;U-937: 100.7
CEP89	CCDC123, FLJ14640	ENSG00000121289	Centrosomal protein 89	19	32875925-32971991	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039382, HPA040056			Supported	Plasma membrane<br>Cytosol	Liver cancer:8.78e-5 (unfavourable)	Expressed in all	Mixed			fallopian tube,prostate: 14.5	Expressed in all		
CHCHD7	COX23, MGC2217	ENSG00000170791	Coiled-coil-helix-coiled-coil-helix domain containing 7	8	56211686-56218798	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA050783	Approved		Approved	Cell Junctions<br>Aggresome	Endometrial cancer:1.39e-6 (unfavourable), Renal cancer:9.47e-5 (favourable)	Expressed in all	Expressed in all			ovary: 61.6	Expressed in all		
CHD4	Mi-2b, Mi2-BETA	ENSG00000111642	Chromodomain helicase DNA binding protein 4	12	6570083-6607476	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA012008	Supported		Enhanced	Nucleus	Liver cancer:6.03e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 119.0	Expressed in all		
CHIC2	BTL	ENSG00000109220	Cysteine rich hydrophobic domain 2	4	54009789-54064690	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA026782, HPA026784, HPA076603	Uncertain		Enhanced	Vesicles<br>Plasma membrane	Renal cancer:1.56e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 63.2	Expressed in all		
CIC	KIAA0306	ENSG00000079432	Capicua transcriptional repressor	19	42268537-42295797	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026388, HPA044341, HPA064725	Approved		Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 54.9	Expressed in all		
CIITA	C2TA, MHC2TA, NLRA	ENSG00000179583	Class II major histocompatibility complex transactivator	16	10866222-10932281	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016084	Enhanced		Approved	Nucleoplasm		Expressed in all	Mixed			lymph node,spleen: 59.2	Cell line enhanced		HDLM-2: 44.9;REH: 81.4
CLIP1	CLIP, CLIP-170, CLIP170, CYLN1, RSN	ENSG00000130779	CAP-Gly domain containing linker protein 1	12	122271432-122422632	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004399, HPA026678	Approved		Supported	Microtubule ends<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 158.6	Expressed in all		
CLP1	hClp1, HEAB	ENSG00000172409	Cleavage and polyadenylation factor I subunit 1	11	57648992-57661868	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA057770	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 17.0	Expressed in all		
CLTC	CLTCL2, Hc	ENSG00000141367	Clathrin heavy chain	17	59619689-59696956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB010389, CAB011571, CAB017155, HPA059143	Approved		Enhanced	Vesicles<br>Mitotic spindle<br>Cytosol	Urothelial cancer:2.02e-4 (unfavourable), Liver cancer:5.54e-4 (unfavourable), Cervical cancer:7.35e-4 (unfavourable), Colorectal cancer:7.65e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 365.5	Expressed in all		
CLTCL1	CHC22, CLH22, CLTCL, CLTD	ENSG00000070371	Clathrin heavy chain like 1	22	19179473-19291716	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA075795			Approved	Vesicles		Mixed	Tissue enhanced		skeletal muscle: 24.1;testis: 49.4	bone marrow: 10.4	Cell line enhanced		HMC-1: 56.9
CNBP	CNBP1, DM2, RNF163, ZCCHC22, ZNF9	ENSG00000169714	CCHC-type zinc finger nucleic acid binding protein	3	129169484-129183922	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA063097			Supported	Nucleus<br>Cytosol	Pancreatic cancer:3.51e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 474.6	Expressed in all		
CNOT3	KIAA0691, LENG2, NOT3, NOT3H	ENSG00000088038	CCR4-NOT transcription complex subunit 3	19	54137728-54155681	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA006408	Approved		Approved	Cytosol	Liver cancer:2.22e-4 (unfavourable), Renal cancer:2.77e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 36.1	Expressed in all		
CNTRL	CEP1, CEP110	ENSG00000119397	Centriolin	9	121074863-121177610	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA020468, HPA020480, HPA051583	Approved		Supported	Centrosome<br>Cytosol	Head and neck cancer:9.21e-5 (favourable)	Expressed in all	Tissue enhanced		testis: 65.8	lymph node: 29.0	Expressed in all		
COL1A1	OI4	ENSG00000108821	Collagen type I alpha 1 chain	17	50183289-50201632	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA008405, HPA011795	Uncertain		Approved	Vesicles<br>Cytosol	Renal cancer:7.19e-12 (unfavourable), Lung cancer:4.43e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 1872.5	Cell line enhanced		BJ: 2487.8;fHDF/TERT166: 3474.4;HSkMC: 1569.1;U-138 MG: 2286.9
COL2A1	AOM, SEDC, STL1	ENSG00000139219	Collagen type II alpha 1 chain	12	47972965-48004486	Cancer-related genes, Disease related genes, Predicted secreted proteins	Evidence at protein level	CAB002214, HPA055753	Supported		Approved	Nucleoplasm		Mixed	Group enriched	9	epididymis: 23.0;stomach: 6.2	prostate: 1.6	Group enriched	23	AF22: 154.1;HAP1: 101.9;HEK93: 33.7
COX6C		ENSG00000164919	Cytochrome c oxidase subunit 6C	8	99873200-99894062	Cancer-related genes, Predicted membrane proteins	Evidence at protein level	HPA014295, CAB016244	Enhanced		Enhanced	Mitochondria		Expressed in all	Expressed in all			duodenum: 339.6	Expressed in all		
CREB1		ENSG00000118260	CAMP responsive element binding protein 1	2	207529737-207603431	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003803, HPA019150	Supported		Enhanced	Nucleoplasm	Liver cancer:2.77e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 59.1	Expressed in all		
CREB3L1	OASIS	ENSG00000157613	CAMP responsive element binding protein 3 like 1	11	46277661-46321422	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA024069, CAB026151	Enhanced		Approved	Plasma membrane<br>Cytosol	Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable)	Expressed in all	Mixed			cervix, uterine: 66.0	Cell line enhanced		fHDF/TERT166: 248.2
CREB3L2	BBF2H7, TCAG_1951439	ENSG00000182158	CAMP responsive element binding protein 3 like 2	7	137874979-138002067	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA015068, HPA015534	Uncertain		Supported	Nucleoplasm<br>Endoplasmic reticulum		Expressed in all	Expressed in all			parathyroid gland: 110.9	Mixed		
CREBBP	CBP, KAT3A, RSTS, RTS	ENSG00000005339	CREB binding protein	16	3725054-3880726	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004212, HPA055861	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.24e-5 (favourable)	Expressed in all	Expressed in all			testis: 61.7	Expressed in all		
CRLF2	CRL2, TSLPR	ENSG00000205755	Cytokine receptor-like factor 2	X	1187549-1212750	Cancer-related genes, Predicted membrane proteins	Evidence at protein level							Tissue enhanced	Tissue enhanced		appendix: 2.1;gallbladder: 2.0	bone marrow: 1.0	Cell line enhanced		HMC-1: 13.5;RPMI-8226: 2.8;U-698: 2.4
CRTC1	FLJ14027, KIAA0616, MECT1, TORC1	ENSG00000105662	CREB regulated transcription coactivator 1	19	18683677-18782333	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA022035	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Pancreatic cancer:1.80e-5 (favourable), Renal cancer:3.83e-5 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 23.7	Expressed in all		
CRTC3	FLJ21868	ENSG00000140577	CREB regulated transcription coactivator 3	15	90529925-90645345	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA043735, HPA063691	Uncertain		Enhanced	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			ovary: 50.7	Mixed		
CSF3R	CD114, GCSFR	ENSG00000119535	Colony stimulating factor 3 receptor	1	36466043-36483278	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB017116, HPA048086	Enhanced				Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable)	Mixed	Tissue enhanced		appendix: 211.2;bone marrow: 243.4;placenta: 147.9	spleen: 96.5	Cell line enhanced		BEWO: 68.2;NB-4: 12.7;THP-1: 32.4;U-937: 36.3
CTCF		ENSG00000102974	CCCTC-binding factor	16	67562407-67639183	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004122, CAB062550, CAB068181, CAB068182	Supported		Supported	Nucleoplasm	Renal cancer:4.06e-4 (favourable), Liver cancer:4.21e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 58.6	Expressed in all		
CTNNB1	armadillo, beta-catenin, CTNNB	ENSG00000168036	Catenin beta 1	3	41194837-41260096	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB000108, CAB001950, HPA029159, HPA029160	Enhanced		Enhanced	Plasma membrane	Colorectal cancer:7.54e-4 (favourable)	Expressed in all	Expressed in all			placenta: 285.6	Expressed in all		
CUX1	CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6	ENSG00000257923	Cut like homeobox 1	7	101815904-102283957	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	HPA003277, HPA003317	Approved		Supported	Nucleoplasm<br>Golgi apparatus	Renal cancer:5.72e-7 (favourable), Glioma:9.90e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 82.5	Expressed in all		
CXCR4	CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R	ENSG00000121966	C-X-C motif chemokine receptor 4	2	136114349-136118165	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters	Evidence at protein level						Renal cancer:1.41e-7 (unfavourable), Ovarian cancer:2.05e-4 (favourable), Stomach cancer:5.67e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 771.6	tonsil: 495.9	Cell line enhanced		Daudi: 410.1;MOLT-4: 425.1;REH: 252.8;U-266/70: 489.0;U-698: 459.8
CYLD	CYLD1, KIAA0849, USPL2	ENSG00000083799	CYLD lysine 63 deubiquitinase	16	50742050-50801935	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB011713, HPA050095	Approved		Supported	Nucleoplasm<br>Microtubule organizing center		Expressed in all	Expressed in all			testis: 70.2	Expressed in all		
DAXX	DAP6	ENSG00000204209	Death domain associated protein	6	33318558-33329286	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB002224, HPA008736, HPA008797, CAB025546, HPA065779	Enhanced		Enhanced	Nucleus<br>Nuclear bodies	Renal cancer:6.32e-7 (unfavourable), Breast cancer:6.05e-4 (favourable)	Expressed in all	Mixed			epididymis: 19.3	Mixed		
DCTN1		ENSG00000204843	Dynactin subunit 1	2	74361154-74392087	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009108, HPA034635	Approved		Supported	Intermediate filaments<br>Centrosome<br>Cytosol	Renal cancer:2.34e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 209.3	Expressed in all		
DDIT3	CHOP, CHOP10, GADD153	ENSG00000175197	DNA damage inducible transcript 3	12	57516588-57520517	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058416, HPA068416	Approved		Supported	Nucleoplasm	Liver cancer:6.55e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 263.6	Expressed in all		
DDR2	NTRKR3, TKT, TYRO10	ENSG00000162733	Discoidin domain receptor tyrosine kinase 2	1	162631373-162787400	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA070112			Supported	Plasma membrane<br>Actin filaments	Renal cancer:1.73e-7 (unfavourable)	Expressed in all	Mixed			adrenal gland: 93.5	Cell line enhanced		ASC diff: 203.0;ASC TERT1: 203.2;BJ hTERT+: 181.9
DDX10	HRH-J8	ENSG00000178105	DEAD-box helicase 10	11	108665025-108940930	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA004691	Approved		Approved	Nucleoli	Renal cancer:2.14e-5 (favourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:5.75e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 29.2	Expressed in all		
DDX3X	DBX, DDX14, DDX3, HLP2	ENSG00000215301	DEAD-box helicase 3, X-linked	X	41333348-41364472	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA001648, HPA005631, HPA059585	Supported	Approved	Approved	Nucleus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 274.6	Expressed in all		
DDX5	G17P1, HLR1, p68	ENSG00000108654	DEAD-box helicase 5	17	64499616-64508199	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005868, HPA020043	Supported		Enhanced	Nucleoplasm	Colorectal cancer:2.12e-4 (favourable)	Expressed in all	Expressed in all			smooth muscle: 599.5	Expressed in all		
DDX6	HLR2, RCK	ENSG00000110367	DEAD-box helicase 6	11	118747766-118791149	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004668, HPA024201, HPA026644	Approved		Supported	Cytosol<br>Cytoplasmic bodies	Liver cancer:6.56e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.6	Expressed in all		
DEK	D6S231E	ENSG00000124795	DEK proto-oncogene	6	18223868-18264823	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015226, HPA054505, HPA057799	Enhanced		Enhanced	Nucleus	Renal cancer:3.45e-4 (unfavourable), Liver cancer:9.65e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 158.8	Mixed		
DICER1	Dicer, HERNA, K12H4.8-LIKE, KIAA0928, MNG1	ENSG00000100697	Dicer 1, ribonuclease III	14	95086228-95158010	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA000694, CAB068185	Approved		Supported	Cytosol		Expressed in all	Expressed in all			placenta: 32.6	Expressed in all		
DNAJB1	Hsp40, HSPF1, RSPH16B, Sis1	ENSG00000132002	DnaJ heat shock protein family (Hsp40) member B1	19	14514770-14529770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB017450, HPA063247	Enhanced		Enhanced	Nucleus<br>Cytosol	Renal cancer:5.96e-4 (favourable)	Expressed in all	Expressed in all			adrenal gland: 348.8	Expressed in all		
DNM2	CMT2M, CMTDI1, CMTDIB, DI-CMTB, DYN2, DYNII	ENSG00000079805	Dynamin 2	19	10718079-10833488	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA054246	Enhanced		Approved	Golgi apparatus<br>Cytosol	Liver cancer:3.63e-4 (unfavourable), Head and neck cancer:8.91e-4 (favourable)	Expressed in all	Expressed in all			colon: 103.9	Expressed in all		
DNMT3A		ENSG00000119772	DNA methyltransferase 3 alpha	2	25227855-25342590	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009469, HPA026588	Approved		Supported	Nucleoplasm	Pancreatic cancer:1.18e-4 (favourable), Endometrial cancer:1.55e-4 (unfavourable), Liver cancer:1.58e-4 (unfavourable), Renal cancer:2.49e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 22.8	Cell line enhanced		NTERA-2: 59.7;SH-SY5Y: 76.5
DROSHA	Etohi2, HSA242976, RN3, RNASE3L, RNASEN	ENSG00000113360	Drosha ribonuclease III	5	31400497-31532196	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:1.39e-4 (unfavourable), Endometrial cancer:6.79e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 30.5	Expressed in all		
EBF1	EBF, OLF1	ENSG00000164330	Early B-cell factor 1	5	158695916-159099761	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061169			Approved	Nucleoplasm<br>Vesicles	Renal cancer:9.62e-7 (unfavourable), Stomach cancer:7.80e-4 (unfavourable)	Mixed	Tissue enhanced		adipose tissue: 41.6	placenta: 16.2	Cell line enhanced		ASC diff: 27.3;HSkMC: 22.6;REH: 81.2
ECT2L	ARHGEF32, C6orf91, FBXO49, LFDH	ENSG00000203734	Epithelial cell transforming 2 like	6	138795926-138904070	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA035488	Uncertain					Not detected	Tissue enriched	7	fallopian tube: 18.3	lung: 2.7	Not detected		
EGFR	ERBB, ERBB1	ENSG00000146648	Epidermal growth factor receptor	7	55019021-55211628	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000035, HPA001200, HPA018530, CAB068186, CAB073534	Enhanced		Enhanced	Plasma membrane	Urothelial cancer:2.04e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 100.0	skin: 58.7	Cell line enriched	15	A-431: 4682.9
EIF3E	eIF3-p48, eIF3e, EIF3S6, INT6	ENSG00000104408	Eukaryotic translation initiation factor 3 subunit E	8	108201216-108435333	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA023973	Approved		Enhanced	Nuclear bodies<br>Cytosol	Renal cancer:3.06e-7 (unfavourable)	Expressed in all	Expressed in all			ovary: 731.0	Expressed in all		
EIF4A2	BM-010, DDX2B, EIF4A, EIF4F	ENSG00000156976	Eukaryotic translation initiation factor 4A2	3	186783205-186789900	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011690, HPA068286	Uncertain		Approved	Cytosol		Expressed in all	Expressed in all			ovary: 726.0	Expressed in all		
ELF4	ELFR, MEF	ENSG00000102034	E74 like ETS transcription factor 4	X	130064874-130110716	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058595, HPA060277	Enhanced		Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:6.49e-6 (unfavourable), Urothelial cancer:1.42e-4 (favourable)	Expressed in all	Mixed			placenta: 34.9	Mixed		
ELK4	SAP1	ENSG00000158711	ELK4, ETS transcription factor	1	205597556-205631962	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA028863	Uncertain		Supported	Nucleoplasm	Renal cancer:2.94e-6 (unfavourable), Head and neck cancer:4.65e-4 (favourable)	Expressed in all	Expressed in all			prostate: 42.8	Expressed in all		
ELL	C19orf17, ELL1, Men, PPP1R68	ENSG00000105656	Elongation factor for RNA polymerase II	19	18442663-18522127	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046076	Uncertain					Expressed in all	Expressed in all			testis: 25.2	Expressed in all		
ELN	SVAS, WBS, WS	ENSG00000049540	Elastin	7	74027789-74069907	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010750, HPA018111, HPA056941	Supported		Approved	Plasma membrane	Thyroid cancer:6.29e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 125.8	Cell line enhanced		BJ: 121.3;fHDF/TERT166: 160.9;U-2197: 748.2
EML4	C2orf2, ELP120, ROPP120	ENSG00000143924	Echinoderm microtubule associated protein like 4	2	42169350-42332548	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA036687, HPA036688, HPA065337	Enhanced		Supported	Intermediate filaments<br>Microtubules<br>Cytosol		Expressed in all	Mixed			placenta: 50.5	Expressed in all		
EP300	KAT3B, p300	ENSG00000100393	E1A binding protein p300	22	41091786-41180079	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000146, HPA003128, HPA004112	Supported		Enhanced	Nucleoplasm	Renal cancer:7.45e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 46.2	Expressed in all		
EPAS1	bHLHe73, HIF2A, HLF, MOP2, PASD2	ENSG00000116016	Endothelial PAS domain protein 1	2	46293667-46386703	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA031200, HPA069697			Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.63e-4 (favourable)	Expressed in all	Expressed in all			placenta: 642.0	Cell line enhanced		U-138 MG: 279.3
EPS15	AF-1P, MLLT5	ENSG00000085832	Epidermal growth factor receptor pathway substrate 15	1	51354263-51519328	Cancer-related genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	HPA008451, CAB010164, HPA061431	Approved		Enhanced	Vesicles<br>Cytosol	Cervical cancer:6.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 84.6	Expressed in all		
ERBB2	CD340, HER-2, HER2, NEU, NGL	ENSG00000141736	Erb-b2 receptor tyrosine kinase 2	17	39687914-39730426	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555	Enhanced		Supported	Plasma membrane<br>Cytosol	Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 124.5	Cell line enriched	22	SK-BR-3: 2343.7
ERBB3	HER3, LCCS2	ENSG00000065361	Erb-b2 receptor tyrosine kinase 3	12	56079857-56103505	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB025331, HPA045396	Uncertain		Approved	Plasma membrane<br>Actin filaments		Expressed in all	Mixed			small intestine: 86.8	Cell line enhanced		Hep G2: 79.5;SK-BR-3: 77.6;SK-MEL-30: 109.7;T-47d: 108.2;WM-115: 145.7
ERBB4	ALS19, HER4	ENSG00000178568	Erb-b2 receptor tyrosine kinase 4	2	211375717-212538841	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	CAB000276, HPA012016, CAB025522	Enhanced					Tissue enhanced	Tissue enhanced		fallopian tube: 17.8	cerebral cortex: 7.6	Group enriched	5	AF22: 6.8;EFO-21: 4.8;HEK93: 3.5;RPTEC TERT1: 4.2;SCLC-21H: 3.7;T-47d: 4.8
ERC1	CAST2, ELKS, KIAA1081, MGC12974, RAB6IP2	ENSG00000082805	ELKS/RAB6-interacting/CAST family member 1	12	990509-1495933	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019513, HPA019523, HPA024130	Approved		Supported	Vesicles<br>Plasma membrane<br>Cytosol	Urothelial cancer:7.01e-4 (unfavourable)	Expressed in all	Mixed			parathyroid gland: 17.1	Expressed in all		
ERG	erg-3, p55	ENSG00000157554	ERG, ETS transcription factor	21	38380027-38661780	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018377, HPA046598	Approved		Approved	Nucleoplasm<br>Cytosol	Cervical cancer:6.18e-6 (unfavourable), Renal cancer:3.94e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 36.8	Cell line enhanced		HUVEC TERT2: 115.5;MOLT-4: 38.1;REH: 138.0;TIME: 92.4
ESR1	Era, ESR, NR3A1	ENSG00000091831	Estrogen receptor 1	6	151656691-152129619	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000037, HPA000449, HPA000450, CAB055099, CAB072858	Enhanced		Approved	Nucleus<br>Vesicles	Endometrial cancer:5.47e-7 (favourable)	Group enriched	Group enriched	8	breast: 37.6;cervix, uterine: 127.8;endometrium: 180.8;fallopian tube: 106.4;smooth muscle: 76.5	seminal vesicle: 13.5	Group enriched	11	MCF7: 34.7;T-47d: 53.2
ETNK1	EKI, EKI1	ENSG00000139163	Ethanolamine kinase 1	12	22625075-22690665	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010712, HPA029407	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable)	Expressed in all	Expressed in all			stomach: 45.6	Expressed in all		
ETV1	ER81	ENSG00000006468	ETS variant 1	7	13891228-13991425	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA077249			Approved	Nucleoplasm		Expressed in all	Tissue enhanced		cerebral cortex: 106.3	lung: 43.1	Cell line enhanced		SCLC-21H: 93.4;U-87 MG: 152.1;WM-115: 77.6
ETV4	E1A-F, E1AF, PEA3	ENSG00000175832	ETS variant 4	17	43527844-43579620	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005768	Approved		Supported	Nucleoli	Liver cancer:2.48e-4 (unfavourable), Thyroid cancer:7.60e-4 (favourable)	Expressed in all	Tissue enhanced		parathyroid gland: 30.3	cerebral cortex: 13.6	Cell line enhanced		AN3-CA: 164.6;SK-MEL-30: 152.6
ETV5	ERM	ENSG00000244405	ETS variant 5	3	186046308-186110318	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009590, HPA063065	Approved		Supported	Nucleoplasm	Liver cancer:7.85e-9 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 114.5	cerebral cortex: 74.7	Cell line enhanced		SK-MEL-30: 141.2
ETV6	TEL	ENSG00000139083	ETS variant 6	12	11649854-11895402	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000264	Enhanced		Enhanced	Nucleoli<br>Cytosol	Renal cancer:4.66e-8 (unfavourable), Urothelial cancer:1.54e-5 (favourable), Pancreatic cancer:9.38e-5 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 26.4	Cell line enhanced		HDLM-2: 80.8
EWSR1	EWS	ENSG00000182944	EWS RNA binding protein 1	22	29268009-29300525	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004230, HPA051771, HPA062953	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:1.27e-6 (unfavourable), Renal cancer:1.21e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 213.6	Expressed in all		
EZH2	ENX-1, EZH1, KMT6, KMT6A	ENSG00000106462	Enhancer of zeste 2 polycomb repressive complex 2 subunit	7	148807383-148884321	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009589	Enhanced		Supported	Nucleoplasm	Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)	Expressed in all	Tissue enhanced		testis: 50.5	bone marrow: 30.0	Expressed in all		
EZR	VIL2	ENSG00000092820	Ezrin	6	158765741-158819412	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004035, HPA021616, CAB047324, CAB075739	Enhanced		Enhanced	Plasma membrane	Renal cancer:9.56e-8 (favourable), Pancreatic cancer:1.70e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 537.0	Expressed in all		
FAM131B	KIAA0773	ENSG00000159784	Family with sequence similarity 131 member B	7	143353400-143362770	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA021371, HPA029992			Enhanced	Nucleoplasm<br>Cytosol		Tissue enriched	Tissue enriched	8	cerebral cortex: 63.8	parathyroid gland: 7.5	Cell line enhanced		CACO-2: 11.5;NTERA-2: 22.2;PC-3: 19.9;SCLC-21H: 25.4
FAM46C	FLJ20202	ENSG00000183508	Family with sequence similarity 46 member C	1	117605934-117628372	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA054049	Uncertain		Approved	Nucleoplasm	Renal cancer:2.77e-5 (favourable), Endometrial cancer:3.75e-5 (favourable)	Expressed in all	Mixed			testis: 58.7	Cell line enhanced		Karpas-707: 208.6;RPMI-8226: 124.6;U-266/70: 61.2
FAS	APO-1, APT1, CD95, FAS1, TNFRSF6	ENSG00000026103	Fas cell surface death receptor	10	88990582-89015785	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA027444	Enhanced		Approved	Plasma membrane<br>Cytosol		Expressed in all	Mixed			rectum: 32.9	Cell line enhanced		Karpas-707: 104.1
FAT1	CDHF7, CDHR8, FAT	ENSG00000083857	FAT atypical cadherin 1	4	186587783-186726722	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA001869, HPA023882	Approved				Lung cancer:4.22e-4 (unfavourable)	Expressed in all	Mixed			smooth muscle: 37.6	Cell line enhanced		fHDF/TERT166: 221.3
FAT4	CDHF14, CDHR11, FAT-J	ENSG00000196159	FAT atypical cadherin 4	4	125316399-125492932	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA052819	Approved		Approved	Cytosol	Renal cancer:1.89e-4 (favourable)	Mixed	Mixed			parathyroid gland: 9.6	Cell line enhanced		HUVEC TERT2: 11.5;TIME: 17.8
FBXO11	FBX11, UBR6	ENSG00000138081	F-box protein 11	2	47789316-47905793	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002690			Supported	Nucleus		Expressed in all	Expressed in all			testis: 75.4	Expressed in all		
FBXW7	AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10	ENSG00000109670	F-box and WD repeat domain containing 7	4	152321259-152536101	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB013793, CAB029987	Supported		Supported	Nucleoplasm<br>Vesicles	Renal cancer:1.52e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 87.4	Expressed in all		
FCGR2B	CD32, CD32B, FCG2, FCGR2	ENSG00000072694	Fc fragment of IgG receptor IIb	1	161663147-161678654	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB007796, HPA014730	Enhanced				Renal cancer:8.82e-4 (unfavourable)	Mixed	Tissue enriched	16	placenta: 576.7	adipose tissue: 36.6	Cell line enhanced		Daudi: 18.5;HMC-1: 27.5;RPMI-8226: 8.1
FCRL4	CD307d, FCRH4, IGFP2, IRTA1	ENSG00000163518	Fc receptor like 4	1	157573749-157598080	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA054030	Approved					Not detected	Tissue enhanced		appendix: 3.6;lymph node: 4.4;tonsil: 9.6	spleen: 1.1	Cell line enriched	36	U-266/70: 3.5
FES	FPS	ENSG00000182511	FES proto-oncogene, tyrosine kinase	15	90883695-90895776	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA001376	Approved		Approved	Nucleus<br>Vesicles<br>Cytosol	Colorectal cancer:5.78e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 96.5	Cell line enhanced		HEL: 56.3;HL-60: 45.0;HMC-1: 100.9;NB-4: 46.6;THP-1: 73.8
FEV	Pet-1	ENSG00000163497	FEV, ETS transcription factor	2	218981087-218985657	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA067679		Supported	Supported	Nuclear speckles	Pancreatic cancer:4.85e-4 (favourable)	Group enriched	Tissue enhanced		adrenal gland: 2.1;duodenum: 2.9;prostate: 1.9;stomach: 2.4	small intestine: 1.6	Group enriched	6	HMC-1: 22.4;SH-SY5Y: 34.6
FGFR1	BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM	ENSG00000077782	Fibroblast growth factor receptor 1	8	38411138-38468834	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB033614, HPA056402, HPA076274	Approved		Supported	Nucleoli		Expressed in all	Expressed in all			cervix, uterine: 109.5	Cell line enhanced		AN3-CA: 602.2
FGFR1OP	FOP	ENSG00000213066	FGFR1 oncogene partner	6	166999182-167052713	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA071876			Supported	Centrosome	Renal cancer:7.32e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 105.4	Expressed in all		
FGFR2	BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25	ENSG00000066468	Fibroblast growth factor receptor 2	10	121478334-121598458	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB010886, HPA035305, HPA056562	Uncertain		Approved	Vesicles	Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable)	Expressed in all	Mixed			skin: 129.4	Cell line enhanced		AN3-CA: 169.6;BEWO: 58.8;HAP1: 61.4;NTERA-2: 58.4
FGFR3	ACH, CD333, CEK2, JTK4	ENSG00000068078	Fibroblast growth factor receptor 3	4	1793307-1808872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB004231, HPA067204	Enhanced		Supported	Endoplasmic reticulum	Endometrial cancer:3.77e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skin: 333.1	cerebral cortex: 49.4	Cell line enhanced		CACO-2: 41.4;Hep G2: 56.1;NTERA-2: 37.4;RT4: 81.0
FGFR4	CD334, JTK2	ENSG00000160867	Fibroblast growth factor receptor 4	5	177086886-177098144	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005196, HPA027273, HPA027369, HPA028251	Approved					Mixed	Tissue enhanced		lung: 38.9	duodenum: 21.4	Cell line enhanced		CACO-2: 142.3;Hep G2: 118.3;RH-30: 260.0
FHIT	AP3Aase, FRA3B	ENSG00000189283	Fragile histidine triad	3	59749310-61251459	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB002684, HPA018840, HPA018909	Enhanced		Approved	Nucleoli fibrillar center<br>Plasma membrane	Renal cancer:1.36e-4 (favourable)	Mixed	Expressed in all			kidney: 26.8	Cell line enhanced		U-266/70: 27.6
FIP1L1	DKFZp586K0717, FIP1	ENSG00000145216	Factor interacting with PAPOLA and CPSF1	4	53377643-53460861	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA037475, HPA058202	Enhanced		Enhanced	Nucleoplasm	Liver cancer:1.51e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 69.8	Expressed in all		
FLI1	EWSR2, SIC-1	ENSG00000151702	Fli-1 proto-oncogene, ETS transcription factor	11	128686535-128813267	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA073099			Supported	Nucleus<br>Nuclear bodies	Renal cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		spleen: 46.1	placenta: 15.6	Cell line enhanced		HEL: 93.0;HUVEC TERT2: 46.8;REH: 44.4;TIME: 47.8
FLT3	CD135, FLK2, STK1	ENSG00000122025	Fms related tyrosine kinase 3	13	28003274-28100592	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	HPA047539			Approved	Endoplasmic reticulum		Tissue enhanced	Tissue enhanced		lymph node: 7.0;spleen: 7.7	appendix: 3.9	Group enriched	14	REH: 38.7;THP-1: 17.4
FLT4	PCL, VEGFR3	ENSG00000037280	Fms related tyrosine kinase 4	5	180601506-180649624	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB000099, HPA046519, HPA067906	Approved		Enhanced	Nuclear speckles<br>Plasma membrane<br>Cell Junctions		Expressed in all	Mixed			spleen: 18.3	Cell line enhanced		BEWO: 11.8;HEK93: 14.1;T-47d: 13.7;TIME: 12.7
FNBP1	FBP17, KIAA0554	ENSG00000187239	Formin binding protein 1	9	129887187-130043194	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019635, HPA019691, HPA022119	Enhanced				Renal cancer:8.45e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 90.7	Mixed		
FOXA1	HNF3A	ENSG00000129514	Forkhead box A1	14	37589984-37596059	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB011595, HPA050505	Enhanced		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Urothelial cancer:1.00e-4 (favourable)	Tissue enhanced	Tissue enhanced		prostate: 146.0	breast: 36.3	Cell line enhanced		MCF7: 98.8;PC-3: 81.2;RT4: 94.9;SK-BR-3: 88.5;T-47d: 157.4
FOXL2	BPES, BPES1	ENSG00000183770	Forkhead box L2	3	138944224-138947140	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA069613	Enhanced		Supported	Nucleus<br>Cytokinetic bridge		Mixed	Tissue enhanced		endometrium: 12.1;ovary: 29.6;parathyroid gland: 24.4	fallopian tube: 7.7	Cell line enhanced		A-431: 4.3;fHDF/TERT166: 4.3;HEL: 7.2;hTCEpi: 5.1;K-562: 7.5;SiHa: 5.9
FOXO1	FKH1, FKHR, FOXO1A	ENSG00000150907	Forkhead box O1	13	40469953-40666597	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001252, CAB022326	Approved	Approved	Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.33e-5 (favourable), Liver cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			ovary: 80.7	Cell line enhanced		HSkMC: 39.2;U-698: 40.3
FOXO3	AF6q21, FKHRL1, FOXO2, FOXO3A	ENSG00000118689	Forkhead box O3	6	108559835-108684774	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004074, HPA063104	Supported		Enhanced	Nucleus		Expressed in all	Expressed in all			ovary: 55.1	Expressed in all		
FOXO4	AFX1, MLLT7	ENSG00000184481	Forkhead box O4	X	71096197-71103535	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	HPA039560, HPA040232	Approved		Supported	Nuclear speckles<br>Cytosol	Renal cancer:3.46e-4 (favourable), Head and neck cancer:4.61e-4 (favourable)	Expressed in all	Expressed in all			placenta: 172.7	Cell line enriched	8	BEWO: 154.9
FOXP1	12CC4, hFKH1B, HSPC215, QRF1	ENSG00000114861	Forkhead box P1	3	70954693-71583989	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003876, CAB011501	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			ovary: 39.7	Expressed in all		
FSTL3	FLRG, FSRP	ENSG00000070404	Follistatin like 3	19	676365-683399	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB024899, HPA045378	Approved		Approved	Nucleoplasm	Lung cancer:4.61e-7 (unfavourable), Ovarian cancer:1.65e-4 (unfavourable), Colorectal cancer:3.01e-4 (unfavourable), Endometrial cancer:3.03e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 260.8	Expressed in all		
FUBP1	FBP, FUBP	ENSG00000162613	Far upstream element binding protein 1	1	77944055-77979110	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006149	Enhanced		Enhanced	Nucleoplasm	Liver cancer:9.83e-9 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 69.5	Expressed in all		
FUS	ALS6, FUS1, hnRNP-P2, HNRNPP2, TLS	ENSG00000089280	FUS RNA binding protein	16	31180110-31194871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008784, CAB033036, CAB058691	Enhanced		Enhanced	Nucleoplasm	Liver cancer:4.38e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 145.8	Expressed in all		
GAS7	KIAA0394, MGC1348	ENSG00000007237	Growth arrest specific 7	17	9910609-10198551	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA004838, HPA064678	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Focal adhesion sites	Urothelial cancer:6.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 154.7	cervix, uterine: 47.6	Cell line enriched	11	WM-115: 526.3
GATA1	ERYF1, GATA-1, GF1, NF-E1, NFE1	ENSG00000102145	GATA binding protein 1	X	48786554-48794311	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000232, HPA000233, CAB009195	Enhanced					Not detected	Tissue enriched	19	bone marrow: 33.2	testis: 1.7	Group enriched	12	HEL: 182.0;HMC-1: 176.5;K-562: 196.6
GATA2	NFE1B	ENSG00000179348	GATA binding protein 2	3	128479427-128493185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005633, CAB024847	Approved		Supported	Nucleoplasm	Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable)	Expressed in all	Tissue enhanced		prostate: 62.7;seminal vesicle: 74.7	endometrium: 40.5	Cell line enhanced		BEWO: 272.0;HEL: 324.7;HMC-1: 165.0;SH-SY5Y: 347.2
GATA3	HDR	ENSG00000107485	GATA binding protein 3	10	8053604-8075198	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB016217, HPA029730	Enhanced		Supported	Nucleoplasm	Renal cancer:3.13e-4 (unfavourable)	Group enriched	Tissue enhanced		parathyroid gland: 235.0;skin: 148.9	placenta: 44.3	Cell line enhanced		BEWO: 172.2;MCF7: 354.3;RT4: 149.5;SH-SY5Y: 145.4;T-47d: 506.9
GMPS		ENSG00000163655	Guanine monophosphate synthase	3	155870536-155944026	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046630			Approved	Cytosol	Liver cancer:8.73e-7 (unfavourable), Endometrial cancer:5.54e-5 (unfavourable), Pancreatic cancer:1.04e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 181.7	Expressed in all		
GNA11	FBH, FBH2, FHH2, HHC2	ENSG00000088256	G protein subunit alpha 11	19	3094410-3124004	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA048886	Approved				Renal cancer:1.48e-11 (favourable), Liver cancer:4.86e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 155.9	Expressed in all		
GNAQ	G-ALPHA-q, GAQ	ENSG00000156052	G protein subunit alpha q	9	77716087-78031458	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB010036, HPA048886	Uncertain		Approved	Nuclear speckles<br>Plasma membrane<br>Cytosol	Renal cancer:1.11e-7 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 84.9	Mixed		
GNAS	GNAS1, GNASXL, GPSA, NESP, NESP55, SCG6, SgVI	ENSG00000087460	GNAS complex locus	20	58839718-58911192	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	CAB010337, HPA018122, HPA027478, HPA028386	Uncertain		Supported	Nucleoplasm<br>Plasma membrane<br>Cytosol	Renal cancer:3.49e-4 (unfavourable), Ovarian cancer:8.76e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 1473.9	Expressed in all		
GOLGA5	golgin-84, GOLIM5, ret-II, rfg5	ENSG00000066455	Golgin A5	14	92794231-92839963	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA000992, HPA063876	Enhanced	Supported	Supported	Golgi apparatus		Expressed in all	Expressed in all			epididymis: 65.3	Expressed in all		
GOPC	CAL, dJ94G16.2, FIG, GOPC1, PIST	ENSG00000047932	Golgi associated PDZ and coiled-coil motif containing	6	117560269-117602542	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019477, HPA024018	Approved		Enhanced	Golgi apparatus<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 47.9	Expressed in all		
GPHN	KIAA1385	ENSG00000171723	Gephyrin	14	66507407-67181803	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003116, CAB004419, HPA024694	Enhanced		Uncertain	Cytoplasmic bodies	Renal cancer:5.25e-12 (favourable), Urothelial cancer:4.61e-5 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 30.5	Mixed		
GRIN2A	GluN2A, NMDAR2A	ENSG00000183454	Glutamate ionotropic receptor NMDA type subunit 2A	16	9753404-10182754	Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB022725	Enhanced					Mixed	Tissue enhanced		cerebral cortex: 25.8	testis: 6.1	Cell line enhanced		fHDF/TERT166: 3.3;U-138 MG: 4.4
H3F3A	H3.3A, H3F3	ENSG00000163041	H3 histone family member 3A	1	226061851-226072001	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011481, CAB037178, HPA042570	Supported		Supported	Nucleoplasm	Renal cancer:1.21e-6 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 1215.4	Expressed in all		
H3F3B	H3.3B	ENSG00000132475	H3 histone family member 3B	17	75776434-75785893	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB037166, CAB037187, CAB037221, HPA042570	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			bone marrow: 2832.4	Expressed in all		
HERPUD1	HERP, KIAA0025, Mif1, SUP	ENSG00000051108	Homocysteine inducible ER protein with ubiquitin like domain 1	16	56932048-56944863	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB037041, CAB037104, HPA040754, HPA041219	Approved		Uncertain	Plasma membrane<br>Cytosol	Renal cancer:1.41e-9 (favourable)	Expressed in all	Expressed in all			thyroid gland: 358.8	Expressed in all		
HEY1	bHLHb31, CHF-2, CHF2, HERP2, HESR-1, HESR1, HRT-1	ENSG00000164683	Hes related family bHLH transcription factor with YRPW motif 1	8	79764010-79767863	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA055599, HPA063472	Uncertain		Approved	Nucleoplasm<br>Nuclear membrane<br>Cytosol		Expressed in all	Tissue enhanced		cerebral cortex: 96.4	placenta: 28.8	Cell line enhanced		HEK93: 120.1;SK-MEL-30: 70.9
HIF1A	bHLHe78, HIF-1alpha, HIF1, MOP1, PASD8	ENSG00000100644	Hypoxia inducible factor 1 alpha subunit	14	61695513-61748259	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA000907, HPA001275, CAB017442	Supported		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane		Expressed in all	Expressed in all			bone marrow: 292.4	Mixed		
HIP1	ILWEQ	ENSG00000127946	Huntingtin interacting protein 1	7	75533300-75738962	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA013606, CAB015334, CAB016402, HPA017964	Enhanced		Enhanced	Vesicles		Expressed in all	Mixed			testis: 35.2	Mixed		
HIST1H3B	H3/l, H3FL	ENSG00000274267	Histone cluster 1 H3 family member b	6	26031650-26032060	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA042570	Supported					Mixed	Tissue enriched	6	bone marrow: 6.1	lymph node: 0.9	Mixed		
HIST1H4I	H4/m, H4FM	ENSG00000276180	Histone cluster 1 H4 family member i	6	27138588-27139881	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA042201	Supported				Renal cancer:1.32e-5 (unfavourable), Cervical cancer:9.70e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 6.1	Cell line enhanced		K-562: 67.9;SiHa: 46.7;U-2 OS: 76.3;U-266/84: 55.8
HLA-A		ENSG00000206503	Major histocompatibility complex, class I, A	6	29941260-29945884	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB078470			Supported	Golgi apparatus<br>Plasma membrane	Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable)	Expressed in all	Mixed			gallbladder: 340.9	Cell line enhanced		A-431: 1127.9
HLF	MGC33822	ENSG00000108924	HLF, PAR bZIP transcription factor	17	55265012-55325065	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA068156, HPA071210			Enhanced	Nucleus	Lung cancer:2.71e-7 (favourable), Renal cancer:3.55e-6 (favourable), Head and neck cancer:1.88e-4 (favourable)	Tissue enhanced	Mixed			cerebral cortex: 65.4	Group enriched	5	HDLM-2: 25.3;Hep G2: 110.7
HMGA1	HMGIY	ENSG00000137309	High mobility group AT-hook 1	6	34236873-34246231	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB032200	Uncertain		Approved	Nucleus<br>Nucleoli	Liver cancer:1.29e-6 (unfavourable), Lung cancer:3.36e-4 (unfavourable), Endometrial cancer:7.13e-4 (unfavourable), Pancreatic cancer:8.71e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 163.8	Expressed in all		
HMGA2	BABL, HMGIC, LIPO	ENSG00000149948	High mobility group AT-hook 2	12	65824131-65966295	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017809, HPA039076	Approved		Supported	Nucleus<br>Nucleoli	Urothelial cancer:2.86e-4 (unfavourable), Head and neck cancer:4.79e-4 (unfavourable)	Mixed	Tissue enhanced		testis: 3.7	bone marrow: 2.9	Cell line enhanced		AF22: 292.5
HNF1A	HNF1, LFB1, MODY3, TCF1	ENSG00000135100	HNF1 homeobox A	12	120978543-121002512	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010430, HPA035231	Enhanced		Supported	Nucleoplasm		Mixed	Tissue enhanced		duodenum: 15.5;kidney: 10.6;small intestine: 15.7	liver: 6.3	Group enriched	7	A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
HNRNPA2B1	HNRPA2B1	ENSG00000122566	Heterogeneous nuclear ribonucleoprotein A2/B1	7	26189927-26201529	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001666, HPA005812, CAB012403, HPA065537	Supported		Enhanced	Nucleoplasm	Liver cancer:1.03e-6 (unfavourable), Renal cancer:8.01e-5 (unfavourable), Prostate cancer:5.12e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 753.7	Expressed in all		
HOOK3	HK3	ENSG00000168172	Hook microtubule tethering protein 3	8	42896932-43030539	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA024756	Approved		Supported	Golgi apparatus<br>Microtubule organizing center<br>Cytosol	Renal cancer:1.32e-4 (unfavourable)	Expressed in all	Mixed			thyroid gland: 36.6	Expressed in all		
HOXA11	HOX1, HOX1I	ENSG00000005073	Homeobox A11	7	27181510-27185223	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006770, HPA035623	Enhanced		Supported	Nucleoplasm	Renal cancer:2.57e-5 (unfavourable)	Mixed	Tissue enhanced		endometrium: 96.3;smooth muscle: 68.5	cervix, uterine: 17.9	Cell line enhanced		HEK93: 46.1;U-937: 37.5
HOXA13	HOX1, HOX1J	ENSG00000106031	Homeobox A13	7	27193503-27200106	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Tissue enhanced	Tissue enhanced		cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5	rectum: 13.0	Cell line enhanced		HAP1: 27.6;HEK93: 34.0;RT4: 33.4
HOXA9	HOX1, HOX1G	ENSG00000078399	Homeobox A9	7	27162435-27175180	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA061982	Uncertain		Supported	Nucleus		Mixed	Mixed			kidney: 12.6	Cell line enhanced		HEK93: 113.8;SCLC-21H: 133.7
HOXC13	HOX3, HOX3G	ENSG00000123364	Homeobox C13	12	53938765-53946544	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051634	Supported					Mixed	Tissue enriched	8	skin: 4.6	breast,testis: 0.5	Cell line enhanced		AN3-CA: 28.1;HaCaT: 56.8;SK-BR-3: 26.3;T-47d: 25.6
HOXD11	HOX4, HOX4F	ENSG00000128713	Homeobox D11	2	176104216-176109754	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at transcript level	HPA055155			Approved	Nucleoplasm		Mixed	Tissue enhanced		endometrium: 4.2	seminal vesicle: 1.3	Cell line enhanced		HEK93: 18.4;SCLC-21H: 7.0;U-251 MG: 3.8
HOXD13	HOX4I, SPD	ENSG00000128714	Homeobox D13	2	176092891-176095938	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA064064			Supported	Nucleus	Colorectal cancer:6.95e-5 (unfavourable)	Mixed	Group enriched	8	cervix, uterine: 7.9;colon: 4.9;prostate: 16.9;rectum: 9.5;seminal vesicle: 24.5	urinary bladder: 1.5	Cell line enhanced		HAP1: 20.6;HEK93: 52.3;HL-60: 52.4;NB-4: 24.7;SCLC-21H: 19.3
HRAS	HRAS1	ENSG00000174775	HRas proto-oncogene, GTPase	11	532242-537287	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB002015, HPA049830	Approved				Liver cancer:2.32e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 25.0	Expressed in all		
HSP90AA1	FLJ31884, Hsp89, Hsp90, HSP90N, HSPC1, HSPCA	ENSG00000080824	Heat shock protein 90 alpha family class A member 1	14	102080738-102139699	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002058	Approved		Supported	Cytosol	Renal cancer:1.18e-5 (favourable), Liver cancer:3.09e-5 (unfavourable), Breast cancer:5.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 1021.5	Expressed in all		
HSP90AB1	HSPC2, HSPCB	ENSG00000096384	Heat shock protein 90 alpha family class B member 1	6	44246166-44253888	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005230, HPA055729, HPA072606, HPA074351	Enhanced		Supported	Cytosol	Ovarian cancer:4.03e-4 (favourable), Renal cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1461.8	Expressed in all		
IDH1		ENSG00000138413	Isocitrate dehydrogenase (NADP(+)) 1, cytosolic	2	208236227-208266074	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB033218, HPA035248, HPA057936, CAB062556	Enhanced		Approved	Nuclear bodies<br>Cytosol	Renal cancer:2.45e-5 (unfavourable), Liver cancer:6.93e-5 (unfavourable)	Expressed in all	Expressed in all			prostate: 338.1	Expressed in all		
IDH2		ENSG00000182054	Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial	15	90083045-90102504	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA007831	Enhanced		Supported	Mitochondria	Cervical cancer:5.15e-5 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 450.0	Expressed in all		
IKBKB	IKK-beta, IKK2, IKKB, NFKBIKB	ENSG00000104365	Inhibitor of nuclear factor kappa B kinase subunit beta	8	42271302-42332653	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001249, CAB004447	Enhanced		Approved	Cytosol	Urothelial cancer:1.46e-6 (favourable)	Expressed in all	Mixed			parathyroid gland: 18.7	Expressed in all		
IKZF1	hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1	ENSG00000185811	IKAROS family zinc finger 1	7	50304124-50405101	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB009247, HPA035221, HPA035222	Enhanced		Supported	Nucleoplasm	Cervical cancer:2.02e-4 (favourable), Breast cancer:4.28e-4 (favourable), Head and neck cancer:8.63e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 83.0	tonsil: 55.9	Cell line enhanced		HDLM-2: 172.0;HMC-1: 152.5;MOLT-4: 116.9;REH: 122.5;U-698: 108.4
IL2	IL-2, TCGF	ENSG00000109471	Interleukin 2	4	122451470-122456725	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted secreted proteins	Evidence at protein level	CAB010310	Uncertain					Not detected	Not detected			rectum,small intestine,tonsil: 0.3	Not detected		
IL21R	CD360	ENSG00000103522	Interleukin 21 receptor	16	27402162-27452042	Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA042296	Uncertain		Uncertain	Plasma membrane<br>Cytosol	Head and neck cancer:7.29e-4 (favourable)	Mixed	Tissue enhanced		appendix: 15.8;lymph node: 28.8;tonsil: 17.4	spleen: 7.5	Cell line enhanced		HDLM-2: 102.6;Karpas-707: 35.4;RH-30: 36.0;RPMI-8226: 42.7
IL6ST	CD130, GP130	ENSG00000134352	Interleukin 6 signal transducer	5	55935095-55994993	Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010558, CAB025784	Uncertain		Supported	Golgi apparatus<br>Plasma membrane	Renal cancer:5.05e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 329.8	Expressed in all		
IL7R	CD127	ENSG00000168685	Interleukin 7 receptor	5	35852695-35879603	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB010215	Approved		Approved	Plasma membrane<br>Microtubule organizing center		Expressed in all	Tissue enhanced		appendix: 182.9;lymph node: 158.5	tonsil: 112.9	Cell line enhanced		fHDF/TERT166: 149.9;HBF TERT88: 165.6;REH: 372.0
IRF4	LSIRF, MUM1	ENSG00000137265	Interferon regulatory factor 4	6	391739-411447	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002038, HPA002698, CAB013508	Enhanced		Supported	Nucleoplasm	Head and neck cancer:1.64e-6 (favourable), Breast cancer:6.44e-4 (favourable)	Tissue enriched	Tissue enhanced		lymph node: 27.1	tonsil: 24.1	Group enriched	5	HDLM-2: 204.2;Karpas-707: 141.1;RPMI-8226: 136.6;U-266/70: 134.4;U-266/84: 98.3;U-698: 40.9;WM-115: 106.9
ITK	EMT, LYK, PSCTK2	ENSG00000113263	IL2 inducible T-cell kinase	5	157142933-157255191	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level							Mixed	Tissue enhanced		appendix: 20.2;lymph node: 33.2;tonsil: 22.3	spleen: 14.0	Cell line enhanced		HDLM-2: 3.2;HEL: 3.4;HMC-1: 3.8;MOLT-4: 18.7
JAK1	JAK1A, JAK1B, JTK3	ENSG00000162434	Janus kinase 1	1	64833229-64966504	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013088	Approved				Renal cancer:2.67e-4 (favourable), Colorectal cancer:2.81e-4 (favourable), Breast cancer:9.63e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 115.6	Expressed in all		
JAK2	JTK10	ENSG00000096968	Janus kinase 2	9	4984390-5128183	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013089, HPA040820, HPA043870	Approved		Supported	Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites		Expressed in all	Mixed			appendix: 28.1	Group enriched	6	ASC diff: 34.8;HDLM-2: 71.3;HEL: 140.3
JAK3	JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK	ENSG00000105639	Janus kinase 3	19	17824780-17848071	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA070314	Enhanced				Renal cancer:2.89e-14 (unfavourable), Cervical cancer:6.42e-5 (favourable)	Expressed in all	Tissue enhanced		appendix: 48.4;lymph node: 46.6	tonsil: 27.2	Cell line enhanced		HDLM-2: 33.0;Karpas-707: 28.7;U-266/84: 17.1;U-937: 18.8
JAZF1	DKFZp761K2222, TIP27, ZNF802	ENSG00000153814	JAZF zinc finger 1	7	27830573-28180743	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB019271, HPA066967	Approved		Supported	Nucleus<br>Nucleoli fibrillar center		Expressed in all	Expressed in all			adrenal gland: 112.8	Mixed		
JUN	AP-1, c-Jun	ENSG00000177606	Jun proto-oncogene, AP-1 transcription factor subunit	1	58780788-58784327	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB003801, CAB007780, HPA059474	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 314.6	Cell line enhanced		RH-30: 282.2
KAT6A	MOZ, MYST3, RUNXBP2, ZC2HC6A, ZNF220	ENSG00000083168	Lysine acetyltransferase 6A	8	41929479-42051990	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017023, HPA063266, HPA065052	Supported		Approved	Nucleoli<br>Nuclear speckles<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 34.5	Expressed in all		
KAT6B	Morf, MOZ2, MYST4, qkf, querkopf, ZC2HC6B	ENSG00000156650	Lysine acetyltransferase 6B	10	74825582-75032622	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006104	Supported		Approved	Nucleus<br>Nuclear bodies	Renal cancer:4.82e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 17.3	Expressed in all		
KCNJ5	CIR, GIRK4, KATP1, Kir3.4, LQT13	ENSG00000120457	Potassium voltage-gated channel subfamily J member 5	11	128891356-128921035	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels	Evidence at protein level	HPA014722, HPA017353, CAB022569	Enhanced					Mixed	Tissue enhanced		adrenal gland: 84.8	spleen: 18.8	Cell line enriched	12	HBEC3-KT: 9.5
KDM5A	JARID1A, RBBP2	ENSG00000073614	Lysine demethylase 5A	12	280129-389454	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA006201			Supported	Nuclear bodies<br>Cytosol		Expressed in all	Expressed in all			testis: 39.0	Expressed in all		
KDM5C	DXS1272E, JARID1C, MRX13, SMCX, XE169	ENSG00000126012	Lysine demethylase 5C	X	53191321-53225422	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA038244, HPA046147			Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:2.11e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 66.7	Expressed in all		
KDM6A	UTX	ENSG00000147050	Lysine demethylase 6A	X	44873177-45112602	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000568, HPA001165, HPA002111	Enhanced		Approved	Nucleoli		Expressed in all	Expressed in all			bone marrow: 41.0	Mixed		
KDR	CD309, FLK1, VEGFR, VEGFR2	ENSG00000128052	Kinase insert domain receptor	4	55078477-55125589	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB004028	Enhanced		Supported	Plasma membrane	Renal cancer:7.26e-4 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 119.2	thyroid gland: 54.7	Group enriched	9	HUVEC TERT2: 178.6;TIME: 148.0
KDSR	DHSR, FVT1, SDR35C1	ENSG00000119537	3-ketodihydrosphingosine reductase	18	63327726-63367510	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB003673, HPA044884	Approved				Renal cancer:9.53e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 45.5	Expressed in all		
KEAP1	INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454	ENSG00000079999	Kelch like ECH associated protein 1	19	10486120-10503741	Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005558, CAB025337	Approved		Supported	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Cervical cancer:3.28e-4 (favourable)	Expressed in all	Expressed in all			skeletal muscle: 49.4	Expressed in all		
KIAA1549		ENSG00000122778	KIAA1549	7	138831381-138981318	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA019560	Approved		Approved	Nuclear membrane<br>Intermediate filaments	Renal cancer:3.93e-7 (favourable)	Mixed	Mixed			seminal vesicle: 10.5	Cell line enhanced		SH-SY5Y: 29.9
KIF5B	KNS, KNS1	ENSG00000170759	Kinesin family member 5B	10	32009010-32056431	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009846, HPA037589, HPA037590	Approved		Enhanced	Microtubule organizing center<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 187.6	Expressed in all		
KIT	C-Kit, CD117, PBT, SCFR	ENSG00000157404	KIT proto-oncogene receptor tyrosine kinase	4	54657918-54740715	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	CAB003288, HPA004471, CAB068253, CAB072867, HPA073252	Enhanced	Supported	Supported	Plasma membrane	Renal cancer:5.63e-4 (favourable)	Mixed	Tissue enhanced		breast: 133.6	thyroid gland: 78.7	Group enriched	14	HEL: 220.1;HMC-1: 434.1
KLF4	EZF, GKLF	ENSG00000136826	Kruppel like factor 4	9	107484852-107490482	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002926	Enhanced		Supported	Nucleoplasm	Renal cancer:3.93e-5 (favourable)	Expressed in all	Expressed in all			esophagus: 128.5	Cell line enhanced		hTCEpi: 66.2;U-2197: 130.0
KLF6	BCD1, COPEB, CPBP, GBF, PAC1, ST12, Zf9	ENSG00000067082	Kruppel like factor 6	10	3775996-3785281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013529, HPA069585	Supported		Approved	Nucleus<br>Nucleoli fibrillar center<br>Vesicles<br>Cytosol	Renal cancer:2.28e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 323.6	Expressed in all		
KLK2		ENSG00000167751	Kallikrein related peptidase 2	19	50861568-50880567	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA000764	Supported					Tissue enriched	Tissue enriched	192	prostate: 867.2	testis: 4.5	Cell line enhanced		NB-4: 3.6
KMT2A	ALL-1, CXXC7, HRX, HTRX1, MLL, MLL1A, TRX1	ENSG00000118058	Lysine methyltransferase 2A	11	118436490-118526832	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017794, CAB024270, HPA044910	Enhanced		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 31.0	Expressed in all		
KMT2C	HALR, KIAA1506, MLL3	ENSG00000055609	Lysine methyltransferase 2C	7	152134922-152436005	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074736			Supported	Nucleoplasm	Renal cancer:8.01e-6 (favourable)	Expressed in all	Expressed in all			skin: 25.0	Expressed in all		
KMT2D	ALR, CAGL114, MLL2, MLL4, TNRC21	ENSG00000167548	Lysine methyltransferase 2D	12	49018975-49059774	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA035977	Approved		Approved	Nucleus<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 46.6	Expressed in all		
KNL1	AF15Q14, CASC5, CT29, D40, hKNL-1, hSpc105, KIAA1570, MCPH4, PPP1R55, Spc7	ENSG00000137812	Kinetochore scaffold 1	15	40594020-40664342	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA026624, HPA049647	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Lung cancer:2.11e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 31.7	lymph node: 4.4	Mixed		
KRAS	KRAS1, KRAS2	ENSG00000133703	KRAS proto-oncogene, GTPase	12	25204789-25250936	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA049830	Approved				Renal cancer:2.75e-5 (favourable), Pancreatic cancer:3.59e-4 (unfavourable)	Expressed in all	Expressed in all			rectum: 32.6	Expressed in all		
KTN1	CG1, KIAA0004, KNT	ENSG00000126777	Kinectin 1	14	55559072-55701526	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003178, CAB015331, HPA017876	Enhanced		Enhanced	Endoplasmic reticulum	Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 268.4	Expressed in all		
LASP1	Lasp-1, MLN50	ENSG00000002834	LIM and SH3 protein 1	17	38869859-38921770	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012072, CAB022049	Enhanced		Supported	Plasma membrane<br>Focal adhesion sites<br>Cytosol	Liver cancer:2.41e-4 (unfavourable), Endometrial cancer:4.57e-4 (unfavourable)	Expressed in all	Expressed in all			small intestine: 181.3	Expressed in all		
LCK		ENSG00000182866	LCK proto-oncogene, Src family tyrosine kinase	1	32251239-32286165	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003494, CAB003816	Enhanced		Approved	Golgi apparatus	Endometrial cancer:2.96e-6 (favourable), Renal cancer:2.60e-5 (unfavourable), Melanoma:5.65e-5 (favourable), Head and neck cancer:2.91e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 125.9;tonsil: 72.4	appendix: 66.3	Group enriched	7	MOLT-4: 429.5;U-698: 207.6
LCP1	CP64, L-PLASTIN, LC64P, PLS2	ENSG00000136167	Lymphocyte cytosolic protein 1	13	46125920-46211871	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019493, CAB020673	Enhanced		Approved	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			lymph node: 614.4	Cell line enhanced		HDLM-2: 728.6;HL-60: 666.2;HMC-1: 741.0;U-698: 751.3
LEF1	TCF10, TCF1ALPHA, TCF7L3	ENSG00000138795	Lymphoid enhancer binding factor 1	4	108047545-108168956	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002087, CAB019405	Enhanced		Approved	Nucleoplasm	Renal cancer:2.47e-6 (unfavourable), Endometrial cancer:1.37e-5 (favourable)	Expressed in all	Tissue enhanced		lymph node: 41.7	tonsil: 28.3	Group enriched	6	MOLT-4: 512.4;REH: 443.8
LHFP	MGC22429	ENSG00000183722	Lipoma HMGIC fusion partner	13	39342892-39603528	Cancer-related genes, Disease related genes, Predicted membrane proteins	Evidence at protein level	HPA058975	Approved		Approved	Nucleoli	Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable)	Expressed in all	Mixed			placenta: 196.1	Cell line enhanced		ASC diff: 177.4;HSkMC: 137.4
LIFR	CD118	ENSG00000113594	Leukemia inhibitory factor receptor alpha	5	38474963-38608354	Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA004478, CAB010252	Approved		Approved	Nuclear speckles<br>Golgi apparatus	Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable)	Mixed	Mixed			thyroid gland: 68.0	Cell line enhanced		AF22: 93.6;SCLC-21H: 72.8
LMNA	CMD1A, HGPS, LGMD1B, LMN1, LMNL1, MADA, PRO1	ENSG00000160789	Lamin A/C	1	156082573-156140089	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004022, HPA006660	Supported					Expressed in all	Expressed in all			gallbladder: 343.4	Expressed in all		
LMO1	RBTN1, RHOM1, TTG1	ENSG00000166407	LIM domain only 1	11	8224304-8268716	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level							Tissue enriched	Tissue enhanced		skeletal muscle: 10.1;skin: 5.9	epididymis: 2.0	Group enriched	6	HeLa: 22.0;SCLC-21H: 14.8;SH-SY5Y: 41.0;SiHa: 8.4
LMO2	RBTN2, RBTNL1, RHOM2, TTG2	ENSG00000135363	LIM domain only 2	11	33858576-33892289	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB016258, HPA029285	Approved		Approved	Nucleoplasm<br>Cytosol	Liver cancer:3.12e-4 (favourable)	Expressed in all	Mixed			spleen: 25.7	Cell line enhanced		HEL: 48.0;HL-60: 42.9;K-562: 49.4;THP-1: 47.5
LPP		ENSG00000145012	LIM domain containing preferred translocation partner in lipoma	3	188153284-188890671	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA011133, HPA017342	Enhanced		Enhanced	Focal adhesion sites<br>Cytosol		Expressed in all	Expressed in all			smooth muscle: 117.9	Cell line enhanced		EFO-21: 109.0;U-698: 138.0
LRIG3	FLJ90440, KIAA3016	ENSG00000139263	Leucine rich repeats and immunoglobulin like domains 3	12	58872149-58920522	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA010773	Approved		Approved	Cytosol		Expressed in all	Tissue enhanced		thyroid gland: 97.8	skin: 33.0	Mixed		
LRP1B	LRP-DIT, LRPDIT	ENSG00000168702	LDL receptor related protein 1B	2	140231423-142131701	Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA069094, HPA074788	Approved		Approved	Vesicles		Tissue enhanced	Tissue enhanced		cerebral cortex: 16.4;thyroid gland: 9.6	epididymis: 2.7	Cell line enhanced		ASC diff: 1.0;HEK93: 1.5;U-138 MG: 1.8
LSM14A	C19orf13, DKFZP434D1335, FAM61A, RAP55, RAP55A	ENSG00000257103	LSM14A, mRNA processing body assembly factor	19	34172504-34229515	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017961	Approved		Supported	Cytosol<br>Cytoplasmic bodies		Expressed in all	Mixed			thyroid gland: 37.5	Cell line enhanced		THP-1: 32.4
LYL1	bHLHa18	ENSG00000104903	LYL1, basic helix-loop-helix family member	19	13099033-13103161	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA075004			Approved	Golgi apparatus	Renal cancer:3.89e-4 (unfavourable)	Expressed in all	Tissue enhanced		bone marrow: 22.9;spleen: 20.7	appendix: 14.3	Cell line enhanced		HEL: 113.5;HMC-1: 179.8;K-562: 90.4;NB-4: 82.5;REH: 87.2
LZTR1	BTBD29, LZTR-1	ENSG00000099949	Leucine zipper like transcription regulator 1	22	20979462-20999038	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068772, HPA071248	Approved				Liver cancer:5.15e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 25.9	Expressed in all		
MAF	c-MAF	ENSG00000178573	MAF bZIP transcription factor	16	79585843-79600714	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010296, HPA028289	Approved				Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 149.6	small intestine: 91.3	Group enriched	9	Karpas-707: 148.6;RPMI-8226: 242.2
MAFB	KRML	ENSG00000204103	MAF bZIP transcription factor B	20	40685848-40689240	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005653	Approved		Approved	Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol	Endometrial cancer:5.64e-4 (unfavourable)	Expressed in all	Tissue enriched	7	parathyroid gland: 689.3	spleen: 102.0	Cell line enhanced		HSkMC: 20.7;hTCEpi: 44.3;SCLC-21H: 19.6;SiHa: 16.5;U-138 MG: 16.2;U-2197: 22.6;U-87 MG: 15.7
MALT1	MLT, PCASP1	ENSG00000172175	MALT1 paracaspase	18	58671386-58754477	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004494, HPA048432	Enhanced		Supported	Nucleoli<br>Cytosol		Expressed in all	Expressed in all			lymph node: 34.0	Expressed in all		
MAML2	KIAA1819, MAM3	ENSG00000184384	Mastermind like transcriptional coactivator 2	11	95976598-96343180	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA035223	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol	Renal cancer:1.90e-4 (favourable), Pancreatic cancer:3.89e-4 (unfavourable)	Expressed in all	Mixed			placenta: 17.5	Cell line enhanced		HDLM-2: 48.9
MAP2K1	MAPKK1, MEK1, PRKMK1	ENSG00000169032	Mitogen-activated protein kinase kinase 1	15	66386817-66492312	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003834, HPA026430	Approved		Enhanced	Plasma membrane<br>Cytosol	Glioma:2.68e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 144.4	Expressed in all		
MAP2K2	MEK2, PRKMK2	ENSG00000126934	Mitogen-activated protein kinase kinase 2	19	4090321-4124129	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB003835, HPA051993	Supported		Supported	Cytosol	Stomach cancer:5.43e-5 (favourable), Cervical cancer:3.72e-4 (favourable), Head and neck cancer:7.98e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 135.0	Expressed in all		
MAP2K4	JNKK1, MEK4, MKK4, PRKMK4, SERK1	ENSG00000065559	Mitogen-activated protein kinase kinase 4	17	12020824-12143830	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB007751, HPA060074	Enhanced		Approved	Nucleoplasm<br>Cell Junctions		Expressed in all	Expressed in all			cerebral cortex: 64.0	Expressed in all		
MAP3K1	MAPKKK1, MEKK, MEKK1	ENSG00000095015	Mitogen-activated protein kinase kinase kinase 1	5	56815574-56896152	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB004500, HPA046509	Approved		Approved	Cytosol		Expressed in all	Mixed			spleen: 28.3	Cell line enhanced		SH-SY5Y: 55.9
MAP3K13	LZK, MEKK13	ENSG00000073803	Mitogen-activated protein kinase kinase kinase 13	3	185282941-185489097	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA016497, HPA036691, HPA036692	Uncertain		Approved	Nucleoplasm<br>Microtubule organizing center<br>Cytosol	Endometrial cancer:1.28e-5 (unfavourable), Pancreatic cancer:7.27e-5 (unfavourable), Ovarian cancer:1.11e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 69.3	Mixed		
MAPK1	ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2	ENSG00000100030	Mitogen-activated protein kinase 1	22	21754500-21867680	Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA003995, CAB004229, HPA005700, HPA030069	Approved				Liver cancer:4.95e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 132.4	Expressed in all		
MAX	bHLHd4, bHLHd5, bHLHd6, bHLHd7, bHLHd8	ENSG00000125952	MYC associated factor X	14	65006174-65102695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000328, HPA003474	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Thyroid cancer:2.12e-4 (favourable), Renal cancer:5.57e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 78.8	Expressed in all		
MDM2	HDM2, MGC5370	ENSG00000135679	MDM2 proto-oncogene	12	68808176-68850686	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB000086, CAB016303	Supported		Supported	Nucleus	Endometrial cancer:4.51e-7 (favourable), Cervical cancer:3.23e-4 (favourable)	Expressed in all	Expressed in all			rectum: 33.9	Expressed in all		
MDM4	HDMX, MDMX	ENSG00000198625	MDM4, p53 regulator	1	204516379-204558120	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA018919, HPA048821	Approved		Supported	Nucleus	Renal cancer:7.06e-6 (unfavourable), Urothelial cancer:2.49e-4 (favourable), Prostate cancer:9.87e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 37.5	Expressed in all		
MDS2		ENSG00000197880	Myelodysplastic syndrome 2 translocation associated	1	23581495-23640568	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at transcript level	HPA052999	Uncertain					Tissue enhanced	Tissue enhanced		lymph node: 7.7;tonsil: 4.0	spleen: 2.9	Cell line enhanced		Daudi: 1.0;U-266/70: 1.0;U-698: 3.4
MECOM	EVI1, KMT8E, MDS1, MDS1-EVI1, PRDM3	ENSG00000085276	MDS1 and EVI1 complex locus	3	169083499-169663618	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA046537	Supported		Supported	Nuclear speckles	Pancreatic cancer:2.59e-4 (unfavourable)	Mixed	Mixed			stomach: 67.3	Cell line enhanced		HUVEC TERT2: 48.0;RPTEC TERT1: 55.1;RT4: 94.4;TIME: 45.0
MED12	CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230	ENSG00000184634	Mediator complex subunit 12	X	71118556-71142454	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003184, HPA003185	Enhanced		Approved	Nucleoplasm		Expressed in all	Expressed in all			ovary: 26.8	Expressed in all		
MEN1		ENSG00000133895	Menin 1	11	64803510-64811294	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030342	Uncertain		Supported	Nucleoplasm<br>Cytosol	Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 22.3	Expressed in all		
MET	DFNB97, HGFR, RCCP2	ENSG00000105976	MET proto-oncogene, receptor tyrosine kinase	7	116672390-116798386	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB005282, CAB018577, HPA055607	Uncertain		Supported	Plasma membrane<br>Cytosol	Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.0	Mixed		
MITF	bHLHe32, MI, WS2, WS2A	ENSG00000187098	Melanogenesis associated transcription factor	3	69739435-69968337	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB002578, HPA003259	Enhanced				Renal cancer:8.35e-10 (favourable)	Group enriched	Tissue enhanced		cervix, uterine: 80.9;endometrium: 79.3	smooth muscle: 69.5	Cell line enhanced		HMC-1: 78.7;SK-MEL-30: 205.7
MKL1	BSAC, KIAA1438, MAL, MRTF-A	ENSG00000196588	Megakaryoblastic leukemia (translocation) 1	22	40410281-40636702	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030782	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.58e-7 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 51.3	Expressed in all		
MLF1		ENSG00000178053	Myeloid leukemia factor 1	3	158571163-158607252	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level						Endometrial cancer:2.15e-5 (unfavourable), Stomach cancer:5.54e-4 (unfavourable)	Mixed	Tissue enriched	7	testis: 671.8	fallopian tube: 97.0	Cell line enhanced		A-431: 71.8
MLH1	COCA2, FCC2, HNPCC, HNPCC2	ENSG00000076242	MutL homolog 1	3	36993332-37050918	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013294, HPA052707, HPA060714, CAB070868	Supported		Enhanced	Nucleoplasm	Liver cancer:8.24e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 60.0	Mixed		
MLLT1	ENL, LTG19, YEATS1	ENSG00000130382	MLLT1, super elongation complex subunit	19	6210379-6279948	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031166	Approved		Supported	Nucleoplasm	Head and neck cancer:6.03e-5 (favourable)	Expressed in all	Expressed in all			placenta: 61.5	Expressed in all		
MLLT10	AF10	ENSG00000078403	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10	10	21524675-21743630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA005747	Supported		Supported	Nucleoplasm	Head and neck cancer:8.75e-4 (favourable)	Expressed in all	Expressed in all			testis: 177.6	Expressed in all		
MLLT11	AF1Q	ENSG00000213190	Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 11	1	151057758-151068497	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA000540	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:4.25e-12 (unfavourable), Endometrial cancer:4.26e-5 (unfavourable)	Expressed in all	Tissue enriched	5	cerebral cortex: 122.5	parathyroid gland: 24.0	Cell line enhanced		AF22: 129.2;SH-SY5Y: 151.4
MLLT3	AF-9, AF9, YEATS3	ENSG00000171843	MLLT3, super elongation complex subunit	9	20341665-20622543	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001824	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:1.84e-4 (favourable)	Expressed in all	Mixed			thyroid gland: 40.6	Cell line enhanced		HEL: 229.3
MLLT6	AF17, FLJ23480	ENSG00000275023	MLLT6, PHD finger domain containing	17	38705542-38729803	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004021	Approved		Approved	Nucleus	Head and neck cancer:3.98e-4 (favourable), Breast cancer:4.18e-4 (favourable), Pancreatic cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 36.4	Expressed in all		
MN1	MGCR, MGCR1, MGCR1-PEN	ENSG00000169184	MN1 proto-oncogene, transcriptional regulator	22	27748277-27801498	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA003072	Approved		Approved	Nucleoplasm		Mixed	Tissue enhanced		skeletal muscle: 22.0	cerebral cortex: 6.4	Cell line enhanced		AF22: 31.4;RH-30: 12.4;TIME: 16.8;U-2 OS: 17.9;U-2197: 17.1
MNX1	HB9, HLXB9, HOXHB9, SCRA1	ENSG00000130675	Motor neuron and pancreas homeobox 1	7	156994051-157010651	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA071717			Approved	Nucleus<br>Nucleoli<br>Cytosol		Mixed	Tissue enhanced		duodenum: 7.3;small intestine: 6.7	colon: 3.7	Cell line enhanced		AN3-CA: 16.0;EFO-21: 15.3;RPMI-8226: 25.9;SCLC-21H: 22.6
MPL	CD110, TPOR	ENSG00000117400	MPL proto-oncogene, thrombopoietin receptor	1	43337849-43352772	Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level							Not detected	Mixed			ovary: 1.3	Cell line enriched	97	HEL: 51.8
MSH2	COCA1, HNPCC, HNPCC1	ENSG00000095002	MutS homolog 2	2	47402969-47562311	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009572, HPA066845, CAB070867	Supported		Supported	Nucleoplasm<br>Vesicles	Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 32.2	Expressed in all		
MSH6	GTBP	ENSG00000116062	MutS homolog 6	2	47695530-47810101	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009091, HPA028376, HPA028446, CAB070870	Enhanced		Supported	Nucleoplasm<br>Golgi apparatus<br>Vesicles	Renal cancer:1.06e-7 (unfavourable), Endometrial cancer:1.34e-4 (unfavourable), Liver cancer:7.86e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 74.5	Expressed in all		
MSI2		ENSG00000153944	Musashi RNA binding protein 2	17	57255851-57684685	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB022300	Approved		Supported	Cytosol	Renal cancer:9.22e-8 (favourable), Stomach cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 119.2	Expressed in all		
MSN		ENSG00000147065	Moesin	X	65588377-65741931	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000263, CAB010898, HPA011135, HPA011227, CAB047336, CAB047338	Enhanced		Enhanced	Plasma membrane	Renal cancer:1.60e-5 (unfavourable)	Expressed in all	Expressed in all			lung: 420.9	Mixed		
MTCP1	P13MTCP1, p8MTCP1	ENSG00000214827	Mature T-cell proliferation 1	X	155061622-155147937	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA032040			Approved	Nucleoplasm<br>Plasma membrane	Renal cancer:4.52e-8 (unfavourable)	Mixed	Mixed			testis: 8.7	Mixed		
MTOR	FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1	ENSG00000198793	Mechanistic target of rapamycin	1	11106535-11262507	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB069425, HPA071227	Approved		Approved	Vesicles<br>Cytosol	Renal cancer:1.49e-5 (favourable)	Expressed in all	Expressed in all			testis: 62.2	Expressed in all		
MUC1	ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM	ENSG00000185499	Mucin 1, cell surface associated	1	155185824-155192916	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000036, CAB001986, HPA004179, HPA007235, HPA008855	Enhanced				Pancreatic cancer:4.60e-4 (unfavourable)	Expressed in all	Tissue enhanced		lung: 448.0;stomach: 654.1	cervix, uterine: 288.9	Group enriched	7	CAPAN-2: 1005.2;RPTEC TERT1: 654.7;T-47d: 360.0
MYB	c-myb	ENSG00000118513	MYB proto-oncogene, transcription factor	6	135181315-135219173	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017704	Approved		Approved	Nucleus<br>Plasma membrane	Prostate cancer:9.65e-4 (favourable), Stomach cancer:9.87e-4 (favourable)	Tissue enhanced	Tissue enhanced		breast: 26.3;rectum: 29.1	colon: 25.2	Cell line enhanced		HL-60: 173.9;MOLT-4: 321.7;REH: 222.8;THP-1: 230.7;U-937: 145.8
MYC	bHLHe39, c-Myc, MYCC	ENSG00000136997	V-myc avian myelocytomatosis viral oncogene homolog	8	127735434-127741434	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000084, CAB010307, HPA055893, HPA066556	Supported		Enhanced	Nucleoplasm	Renal cancer:5.49e-8 (unfavourable), Urothelial cancer:4.96e-5 (unfavourable), Ovarian cancer:7.52e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 151.6	Expressed in all		
MYCL	bHLHe38, LMYC, MYCL1	ENSG00000116990	V-myc avian myelocytomatosis viral oncogene lung carcinoma derived homolog	1	39895426-39902256	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063132			Supported	Nucleus	Lung cancer:4.49e-4 (favourable)	Expressed in all	Tissue enhanced		skin: 41.6	urinary bladder: 23.7	Group enriched	7	U-266/70: 372.1;U-266/84: 268.8
MYCN	bHLHe37, MYCNOT, N-myc, NMYC	ENSG00000134323	V-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog	2	15940564-15947007	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA057420			Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enhanced		placenta: 13.7	cerebral cortex: 7.2	Cell line enhanced		AF22: 43.5;BEWO: 230.1;HMC-1: 50.4;NTERA-2: 91.1;RH-30: 61.3
MYD88		ENSG00000172936	Myeloid differentiation primary response 88	3	38138478-38143022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009104	Approved		Supported	Vesicles<br>Mitochondria<br>Cytosol	Breast cancer:8.45e-4 (favourable)	Expressed in all	Mixed			lung: 57.1	Expressed in all		
MYH11	SMHC, SMMHC	ENSG00000133392	Myosin heavy chain 11	16	15703172-15857033	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB002302, HPA014539, HPA015310	Enhanced		Approved	Plasma membrane<br>Cytosol	Liver cancer:1.10e-5 (favourable)	Tissue enhanced	Tissue enhanced		seminal vesicle: 1381.0;smooth muscle: 1022.0	prostate: 899.8	Cell line enhanced		BEWO: 1.7;NB-4: 1.2;U-698: 3.4
MYH9	DFNA17, EPSTS, FTNS, MHA, NMHC-II-A, NMMHCA	ENSG00000100345	Myosin heavy chain 9	22	36281281-36388018	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001644, CAB015386, HPA064783	Enhanced		Supported	Plasma membrane<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			spleen: 308.5	Expressed in all		
MYO5A	GS1, MYH12, MYO5, MYR12	ENSG00000197535	Myosin VA	15	52307283-52529050	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001356	Approved		Approved	Focal adhesion sites<br>Microtubule organizing center	Urothelial cancer:4.22e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 96.4	Cell line enhanced		Karpas-707: 145.4
MYOD1	bHLHc1, MYF3, MYOD, PUM	ENSG00000129152	Myogenic differentiation 1	11	17719568-17722131	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051362			Supported	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Tissue enhanced	Tissue enriched	10	skeletal muscle: 9.0	prostate: 0.9	Cell line enriched	17	RH-30: 447.0
NAB2	MADER	ENSG00000166886	NGFI-A binding protein 2	12	57088894-57095476	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004510, HPA027464	Approved		Approved	Nucleus<br>Cytosol	Renal cancer:9.38e-6 (unfavourable), Breast cancer:7.41e-4 (favourable)	Expressed in all	Expressed in all			ovary: 39.3	Expressed in all		
NACA	NACA1	ENSG00000196531	Nascent polypeptide-associated complex alpha subunit	12	56712428-56731628	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA073152, HPA073648			Approved	Cytosol	Renal cancer:4.58e-11 (unfavourable)	Expressed in all	Expressed in all			ovary: 2552.0	Expressed in all		
NCKIPSD	AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH	ENSG00000213672	NCK interacting protein with SH3 domain	3	48673844-48686364	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB019267, HPA050005			Enhanced	Plasma membrane<br>Cytosol	Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable)	Expressed in all	Tissue enriched	9	parathyroid gland: 306.0	cerebral cortex: 35.0	Expressed in all		
NCOA1	bHLHe74, F-SRC-1, KAT13A, NCoA-1, RIP160, SRC1	ENSG00000084676	Nuclear receptor coactivator 1	2	24491914-24770702	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB019402, HPA070213, HPA070520	Enhanced		Enhanced	Nucleoplasm<br>Plasma membrane<br>Cytosol		Expressed in all	Expressed in all			parathyroid gland: 59.0	Expressed in all		
NCOA2	bHLHe75, GRIP1, KAT13C, NCoA-2, TIF2	ENSG00000140396	Nuclear receptor coactivator 2	8	70109762-70403805	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA060243			Supported	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.08e-4 (favourable)	Expressed in all	Expressed in all			epididymis: 36.0	Expressed in all		
NCOA4	ARA70, DKFZp762E1112, ELE1, PTC3, RFG	ENSG00000266412	Nuclear receptor coactivator 4	10	46005088-46030714	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA051260, HPA065208	Uncertain		Approved	Nucleoli<br>Golgi apparatus<br>Cytosol	Renal cancer:8.04e-6 (favourable), Glioma:2.88e-4 (favourable)	Expressed in all	Expressed in all			duodenum: 247.1	Expressed in all		
NCOR1	hCIT529I10, hN-CoR, KIAA1047, MGC104216, N-CoR, PPP1R109, TRAC1	ENSG00000141027	Nuclear receptor corepressor 1	17	16029157-16218185	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043246, HPA050288, HPA051168, CAB072830	Enhanced		Enhanced	Nucleoplasm<br>Cytosol	Renal cancer:7.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 84.7	Expressed in all		
NCOR2	CTG26, SMRT, SMRTE, TNRC14, TRAC-1	ENSG00000196498	Nuclear receptor corepressor 2	12	124324415-124567589	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001928	Approved		Supported	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 81.2	Expressed in all		
NDRG1	CAP43, DRG1, NDR1, RTP, TDD5	ENSG00000104419	N-myc downstream regulated 1	8	133237171-133302022	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA006881	Approved		Supported	Microtubules<br>Cytosol	Liver cancer:1.47e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable), Glioma:7.24e-4 (unfavourable)	Expressed in all	Expressed in all			prostate: 535.2	Cell line enhanced		hTCEpi: 403.8;hTERT-HME1: 857.9;U-87 MG: 734.9
NF1		ENSG00000196712	Neurofibromin 1	17	31094927-31382116	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins	Evidence at protein level	HPA045502	Uncertain		Approved	Mitochondria		Expressed in all	Expressed in all			parathyroid gland: 33.0	Expressed in all		
NF2	ACN, BANF, merlin, SCH	ENSG00000186575	Neurofibromin 2	22	29603556-29698598	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003097, CAB005385	Supported		Enhanced	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.89e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 58.7	Expressed in all		
NFATC2	NF-ATP, NFAT1, NFATp	ENSG00000101096	Nuclear factor of activated T-cells 2	20	51386957-51562831	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008789, CAB018567, HPA024369	Enhanced		Supported	Nucleoplasm<br>Cytosol	Renal cancer:1.57e-4 (unfavourable)	Expressed in all	Expressed in all			gallbladder: 26.8	Cell line enhanced		HDLM-2: 22.7;HMC-1: 23.5;WM-115: 40.4
NFE2L2	NRF2	ENSG00000116044	Nuclear factor, erythroid 2 like 2	2	177227595-177392697	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002990, CAB020317, HPA043438	Enhanced		Approved	Nucleus<br>Plasma membrane<br>Cytosol	Renal cancer:2.26e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 267.1	Expressed in all		
NFIB	NFI-RED, NFIB2, NFIB3	ENSG00000147862	Nuclear factor I B	9	14081843-14398983	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003956	Supported		Supported	Nucleus<br>Nucleoli fibrillar center	Renal cancer:3.53e-4 (favourable)	Expressed in all	Mixed			breast: 44.5	Cell line enhanced		AN3-CA: 151.3
NFKB2	LYT-10, NF-kB2, p105, p49/p100, p52	ENSG00000077150	Nuclear factor kappa B subunit 2	10	102394110-102402529	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA008422, CAB022098, HPA023900	Enhanced		Approved	Nucleoplasm<br>Cytosol	Renal cancer:6.69e-12 (unfavourable), Melanoma:8.45e-5 (favourable), Colorectal cancer:3.86e-4 (unfavourable)	Expressed in all	Expressed in all			appendix: 70.7	Expressed in all		
NFKBIE	IKBE	ENSG00000146232	NFKB inhibitor epsilon	6	44258166-44265788	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA002692, HPA005941, CAB010272	Supported		Supported	Nucleus<br>Nucleoli fibrillar center<br>Cytosol	Renal cancer:1.37e-6 (unfavourable), Breast cancer:1.72e-5 (favourable), Liver cancer:3.50e-4 (unfavourable), Urothelial cancer:8.07e-4 (favourable)	Expressed in all	Mixed			spleen: 26.1	Expressed in all		
NIN		ENSG00000100503	Ninein	14	50719763-50831121	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA005939, HPA070691	Enhanced		Enhanced	Nucleus<br>Nucleoli<br>Centrosome		Expressed in all	Mixed			lymph node: 47.5	Expressed in all		
NKX2-1	BCH, NKX2A, TITF1, TTF-1, TTF1	ENSG00000136352	NK2 homeobox 1	14	36516392-36521149	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000078, CAB053633, HPA074316	Enhanced		Uncertain	Golgi apparatus<br>Vesicles		Group enriched	Group enriched	177	lung: 101.3;thyroid gland: 103.5	stomach: 0.5	Cell line enriched	36	SCLC-21H: 119.8
NONO	NMT55, NRB54, P54, P54NRB, PPP1R114	ENSG00000147140	Non-POU domain containing, octamer-binding	X	71283192-71301168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB022069, HPA054094, HPA054559	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:9.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 245.9	Expressed in all		
NOTCH1	TAN1	ENSG00000148400	Notch 1	9	136494444-136545862	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB008112, CAB022466, HPA067168	Supported		Approved	Nucleoplasm	Renal cancer:5.45e-4 (unfavourable)	Expressed in all	Expressed in all			skin: 24.0	Cell line enhanced		MOLT-4: 77.4
NOTCH2		ENSG00000134250	Notch 2	1	119911553-120069626	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA048743	Approved		Supported	Nucleoplasm<br>Plasma membrane	Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 46.7	Mixed		
NPM1	B23, NPM	ENSG00000181163	Nucleophosmin	5	171387116-171411137	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA011384, CAB012983	Supported		Enhanced	Nucleus<br>Nucleoli	Renal cancer:2.89e-6 (unfavourable), Liver cancer:4.82e-6 (unfavourable), Head and neck cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 1800.2	Expressed in all		
NR4A3	CHN, CSMF, MINOR, NOR1	ENSG00000119508	Nuclear receptor subfamily 4 group A member 3	9	99821855-99866891	Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA043360	Uncertain				Breast cancer:5.97e-4 (favourable)	Mixed	Tissue enhanced		adrenal gland: 88.9	urinary bladder: 42.2	Cell line enhanced		BJ hTERT+: 21.0;SK-MEL-30: 14.0;U-266/70: 7.9
NRAS	N-ras	ENSG00000213281	Neuroblastoma RAS viral oncogene homolog	1	114704469-114716894	Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010157, HPA049830	Uncertain				Liver cancer:3.03e-7 (unfavourable), Pancreatic cancer:1.36e-4 (unfavourable), Renal cancer:7.87e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 39.4	Expressed in all		
NRG1	GGF, HGL, HRG, NDF, NRG1-IT2	ENSG00000157168	Neuregulin 1	8	31639386-32767959	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA010964	Uncertain		Approved	Nucleoplasm		Tissue enhanced	Mixed			thyroid gland: 20.0	Cell line enhanced		A549: 130.4;hTEC/SVTERT24-B: 101.2
NSD1	ARA267, FLJ22263, KMT3B, STO	ENSG00000165671	Nuclear receptor binding SET domain protein 1	5	177133025-177300215	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048431, HPA070333, HPA073705	Supported		Supported	Nucleus<br>Plasma membrane		Expressed in all	Expressed in all			testis: 43.2	Mixed		
NSD2	KMT3G, MMSET, WHSC1	ENSG00000109685	Nuclear receptor binding SET domain protein 2	4	1871424-1982207	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015801, CAB068246, CAB068247	Enhanced		Supported	Nucleus	Liver cancer:2.61e-4 (unfavourable), Renal cancer:7.19e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 66.6	Expressed in all		
NSD3	FLJ20353, KMT3F, WHISTLE, WHSC1L1	ENSG00000147548	Nuclear receptor binding SET domain protein 3	8	38269697-38382272	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA005659, CAB013721, HPA018893	Uncertain		Approved	Nucleoplasm<br>Mitochondria	Pancreatic cancer:7.48e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 47.8	Expressed in all		
NT5C2	cN-II, GMP, NT5B, PNT5, SPG65	ENSG00000076685	5'-nucleotidase, cytosolic II	10	103088017-103193306	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA003751	Approved					Expressed in all	Expressed in all			thyroid gland: 119.6	Expressed in all		
NTRK1	MTC, TRK, TRKA	ENSG00000198400	Neurotrophic receptor tyrosine kinase 1	1	156815640-156881850	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins	Evidence at protein level	CAB004606, HPA035799, HPA076570	Approved		Uncertain	Vesicles<br>Cytosol		Tissue enhanced	Tissue enriched	6	adrenal gland: 9.5	testis: 1.6	Cell line enhanced		HDLM-2: 10.4;HEL: 11.9;HMC-1: 69.1;SH-SY5Y: 19.1
NTRK3	TRKC	ENSG00000140538	Neurotrophic receptor tyrosine kinase 3	15	87859751-88256768	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB009233, HPA027484, HPA048065	Enhanced		Supported	Nuclear membrane<br>Nucleoli		Tissue enhanced	Tissue enhanced		cerebral cortex: 39.6	testis: 15.2	Cell line enriched	8	U-138 MG: 99.2
NUMA1		ENSG00000137497	Nuclear mitotic apparatus protein 1	11	72002864-72080693	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019841, HPA019859, HPA029912	Enhanced		Enhanced	Nucleoplasm	Renal cancer:7.92e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 247.9	Expressed in all		
NUP214	CAIN, CAN, D9S46E, N214	ENSG00000126883	Nucleoporin 214	9	131125561-131234670	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters	Evidence at protein level	HPA048789			Supported	Nucleus<br>Vesicles<br>Focal adhesion sites	Renal cancer:2.39e-5 (favourable)	Expressed in all	Expressed in all			testis: 123.0	Expressed in all		
NUP98	NUP96	ENSG00000110713	Nucleoporin 98	11	3671083-3797792	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA074810			Supported	Nucleoplasm<br>Vesicles		Expressed in all	Expressed in all			testis: 150.7	Expressed in all		
NUTM1	C15orf55, DKFZp434O192, FAM22H, NUT	ENSG00000184507	NUT midline carcinoma family member 1	15	34343315-34357737	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040421	Enhanced					Not detected	Tissue enriched	78	testis: 22.5	duodenum,skin: 0.2	Not detected		
NUTM2A	FAM22A	ENSG00000184923	NUT family member 2A	10	87225448-87236908	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level							Not detected	Mixed			skin: 1.9	Cell line enhanced		HMC-1: 8.3
NUTM2B	bA119F19.1, FAM22B	ENSG00000188199	NUT family member 2B	10	79703227-79714681	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level							Not detected	Mixed			testis: 2.2	Mixed		
OLIG2	BHLHB1, bHLHe19, OLIGO2, PRKCBP2, RACK17	ENSG00000205927	Oligodendrocyte transcription factor 2	21	33025845-33029196	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003254, CAB019381	Enhanced		Uncertain	Nucleoplasm<br>Plasma membrane		Tissue enriched	Tissue enriched	245	cerebral cortex: 91.0	duodenum: 0.3	Cell line enhanced		HMC-1: 46.5;NB-4: 25.3;THP-1: 23.2;WM-115: 10.9
OMD	osteoadherin, SLRR2C	ENSG00000127083	Osteomodulin	9	92414245-92424461	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA005731, HPA069948		Approved	Approved	Nucleoli fibrillar center<br>Endoplasmic reticulum		Mixed	Mixed			cervix, uterine: 36.4	Group enriched	13	ASC diff: 6.2;ASC TERT1: 5.9
P2RY8	P2Y8	ENSG00000182162	Purinergic receptor P2Y8	X	1462572-1537107	Cancer-related genes, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003631	Enhanced				Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable)	Expressed in all	Tissue enhanced		lymph node: 47.6	tonsil: 31.3	Cell line enhanced		Daudi: 87.1;U-266/70: 75.0;U-698: 136.4
PAFAH1B2		ENSG00000168092	Platelet activating factor acetylhydrolase 1b catalytic subunit 2	11	117144267-117176894	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA051836	Approved		Supported	Nucleoli<br>Plasma membrane<br>Cytosol	Pancreatic cancer:7.79e-5 (unfavourable), Lung cancer:3.07e-4 (unfavourable), Ovarian cancer:4.25e-4 (favourable), Liver cancer:9.44e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 68.2	Expressed in all		
PATZ1	dJ400N23, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, ZSG	ENSG00000100105	POZ/BTB and AT hook containing zinc finger 1	22	31325804-31346232	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA047893, HPA048315	Approved		Supported	Nucleoplasm	Renal cancer:8.54e-8 (favourable), Urothelial cancer:7.79e-6 (favourable), Glioma:6.53e-5 (favourable), Lung cancer:8.71e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 40.4	Expressed in all		
PAX3	HUP2, WS1	ENSG00000135903	Paired box 3	2	222199888-222298996	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063659, HPA069000	Approved		Supported	Nucleoplasm		Tissue enriched	Group enriched	8	breast: 1.2;skeletal muscle: 1.1;skin: 3.2;testis: 2.4	prostate: 0.2	Cell line enhanced		BJ hTERT+ SV40 Large T+: 9.6;BJ hTERT+ SV40 Large T+ RasG12V: 11.6;RH-30: 16.2;SK-MEL-30: 24.6
PAX5	BSAP	ENSG00000196092	Paired box 5	9	36833275-37034185	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB026269, CAB026869, HPA056394, HPA068498	Enhanced		Approved	Nucleoplasm<br>Vesicles<br>Cytosol		Mixed	Tissue enhanced		lymph node: 48.5;spleen: 26.2;tonsil: 33.2	appendix: 19.5	Group enriched	6	Daudi: 48.5;REH: 181.0;U-698: 61.2
PAX7	Hup1	ENSG00000009709	Paired box 7	1	18631006-18748866	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level							Group enriched	Group enriched	7	cerebral cortex: 1.3;skeletal muscle: 2.2	esophagus,testis: 0.2	Group enriched	7	A549: 1.3;CAPAN-2: 1.4;U-2 OS: 3.5
PAX8		ENSG00000125618	Paired box 8	2	113215997-113278950	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030062, CAB055097, CAB061888, HPA064554	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.75e-5 (unfavourable)	Group enriched	Tissue enriched	10	thyroid gland: 644.0	kidney: 65.2	Group enriched	8	EFO-21: 76.3;RPTEC TERT1: 144.9
PBRM1	BAF180, PB1	ENSG00000163939	Polybromo 1	3	52545352-52685917	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015629, HPA059373	Uncertain		Supported	Nucleoplasm		Expressed in all	Expressed in all			thyroid gland: 44.7	Expressed in all		
PBX1		ENSG00000185630	PBX homeobox 1	1	164555584-164899296	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA003505, HPA003881, CAB018768	Supported		Enhanced	Nucleoplasm		Mixed	Expressed in all			endometrium: 248.2	Cell line enhanced		SK-BR-3: 173.0
PCM1	PTC4	ENSG00000078674	Pericentriolar material 1	8	17922840-18029944	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA023370, HPA023374, CAB058695	Enhanced		Enhanced	Nuclear membrane<br>Centrosome<br>Cytosol		Expressed in all	Expressed in all			testis: 277.4	Expressed in all		
PCSK7	LPC, PC7, PC8, SPC7	ENSG00000160613	Proprotein convertase subtilisin/kexin type 7	11	117204337-117232525	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA043181, HPA052957			Uncertain	Nucleus<br>Nuclear membrane<br>Nucleoli		Expressed in all	Expressed in all			endometrium: 75.4	Expressed in all		
PDCD1LG2	B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2	ENSG00000197646	Programmed cell death 1 ligand 2	9	5510570-5571254	Cancer-related genes, CD markers, Predicted membrane proteins	Evidence at protein level	HPA013411	Approved		Approved	Cytosol	Renal cancer:1.15e-4 (unfavourable)	Mixed	Tissue enhanced		spleen: 21.5	lymph node: 12.0	Cell line enhanced		BJ: 62.0;BJ hTERT+: 93.1;HDLM-2: 83.9
PDE4DIP	CMYA2, KIAA0454, KIAA0477, MMGL	ENSG00000178104	Phosphodiesterase 4D interacting protein	1	148808181-149048286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008162, HPA012678	Uncertain		Supported	Golgi apparatus		Expressed in all	Expressed in all			skeletal muscle: 766.6	Expressed in all		
PDGFB	SIS, SSV	ENSG00000100311	Platelet derived growth factor subunit B	22	39223359-39244751	Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB011604, HPA011972, CAB018341	Supported		Approved	Vesicles	Lung cancer:3.67e-5 (unfavourable)	Expressed in all	Tissue enhanced		placenta: 59.7	lung: 28.6	Cell line enhanced		EFO-21: 65.2;HUVEC TERT2: 45.3;SK-BR-3: 40.1;TIME: 55.5
PDGFRA	CD140a, GAS9, PDGFR2	ENSG00000134853	Platelet derived growth factor receptor alpha	4	54229097-54298247	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	HPA004947, CAB018143	Supported		Supported	Nucleus<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable)	Expressed in all	Expressed in all			ovary: 222.6	Cell line enhanced		ASC diff: 306.3;ASC TERT1: 145.3;BJ hTERT+: 217.9;fHDF/TERT166: 147.1;HHSteC: 126.5;HSkMC: 276.0
PDGFRB	CD140b, JTK12, PDGFR, PDGFR1	ENSG00000113721	Platelet derived growth factor receptor beta	5	150113837-150155872	Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins	Evidence at protein level	CAB003842, CAB018144, HPA028499	Enhanced		Supported	Golgi apparatus<br>Vesicles	Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 193.8	Cell line enhanced		ASC diff: 923.6;ASC TERT1: 324.4
PER1	PER, RIGUI	ENSG00000179094	Period circadian clock 1	17	8140472-8156506	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA047947, HPA067064			Supported	Nucleoplasm<br>Cytosol	Stomach cancer:1.94e-4 (unfavourable), Liver cancer:2.56e-4 (favourable), Cervical cancer:3.89e-4 (favourable)	Expressed in all	Expressed in all			thyroid gland: 70.3	Expressed in all		
PHF6	BFLS, BORJ, CENP-31, KIAA1823, MGC14797	ENSG00000156531	PHD finger protein 6	X	134373253-134428791	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA001023	Enhanced		Enhanced	Nucleus<br>Nucleoli	Liver cancer:3.38e-4 (unfavourable), Pancreatic cancer:9.96e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 41.7	Expressed in all		
PHOX2B	NBPhox, Phox2b, PMX2B	ENSG00000109132	Paired like homeobox 2b	4	41744082-41748970	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA074325, HPA074941			Enhanced	Nucleoplasm		Not detected	Tissue enriched	8	adrenal gland: 10.3	small intestine: 1.2	Cell line enriched	92	SH-SY5Y: 130.2
PICALM	CALM, CLTH	ENSG00000073921	Phosphatidylinositol binding clathrin assembly protein	11	85957684-86069882	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019053, HPA019061	Enhanced		Supported	Vesicles	Renal cancer:2.02e-6 (favourable), Pancreatic cancer:6.61e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 297.2	Expressed in all		
PIK3CA	PI3K	ENSG00000121879	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	3	179148114-179240093	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA009985, CAB017804	Approved		Approved	Cytosol		Expressed in all	Mixed			parathyroid gland: 23.8	Expressed in all		
PIK3R1	GRB1, p85, p85-ALPHA	ENSG00000145675	Phosphoinositide-3-kinase regulatory subunit 1	5	68215720-68301821	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA001216, CAB004268	Approved		Approved	Cytosol	Liver cancer:8.09e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 132.9	Expressed in all		
PIM1	PIM	ENSG00000137193	Pim-1 proto-oncogene, serine/threonine kinase	6	37170203-37175426	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA003941, CAB017040	Uncertain		Supported	Nucleoli<br>Cytosol	Endometrial cancer:9.73e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 133.9	Expressed in all		
PLAG1	ZNF912	ENSG00000181690	PLAG1 zinc finger	8	56160904-56211324	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA072290			Supported	Nuclear speckles		Mixed	Mixed			ovary: 5.9	Mixed		
PLCG1	NCKAP3, PLC-II, PLC1, PLC148, PLCgamma1	ENSG00000124181	Phospholipase C gamma 1	20	41136960-41196801	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB004277, HPA036681, HPA036682	Approved		Supported	Cytosol	Pancreatic cancer:4.72e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 47.6	Expressed in all		
PML	MYL, RNF71, TRIM19	ENSG00000140464	Promyelocytic leukemia	15	73994673-74047812	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008312, CAB010194, CAB016304	Supported		Enhanced	Nuclear bodies	Renal cancer:6.27e-8 (unfavourable), Breast cancer:3.24e-4 (favourable), Pancreatic cancer:3.29e-4 (unfavourable)	Expressed in all	Expressed in all			adipose tissue: 45.1	Expressed in all		
POLE	POLE1	ENSG00000177084	DNA polymerase epsilon, catalytic subunit	12	132623753-132687365	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA058210, HPA067385			Enhanced	Nucleus<br>Plasma membrane	Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 22.1	Expressed in all		
POT1	DKFZp586D211, hPot1	ENSG00000128513	Protection of telomeres 1	7	124822386-124929983	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA068538			Supported	Nucleus		Expressed in all	Mixed			thyroid gland: 21.6	Expressed in all		
POU2AF1	BOB1, OBF1	ENSG00000110777	POU class 2 associating factor 1	11	111352252-111455630	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB011193	Enhanced				Cervical cancer:1.63e-4 (favourable), Breast cancer:1.68e-4 (favourable), Head and neck cancer:3.59e-4 (favourable)	Mixed	Tissue enhanced		lymph node: 101.7;tonsil: 93.7	appendix: 55.5	Cell line enhanced		Daudi: 190.2;Karpas-707: 212.1;U-266/70: 217.7;U-698: 374.3
POU5F1	MGC22487, OCT3, Oct4, OTF3	ENSG00000204531	POU class 5 homeobox 1	6	31164337-31180731	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB025600, CAB026380, HPA058267	Approved		Supported	Nucleoplasm<br>Cytosol	Urothelial cancer:2.04e-5 (favourable)	Tissue enriched	Mixed			fallopian tube: 6.4	Group enriched	12	HAP1: 366.6;NTERA-2: 938.2
PPARG	NR1C3, PPARG1, PPARG2, PPARgamma	ENSG00000132170	Peroxisome proliferator activated receptor gamma	3	12287368-12434356	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004282, HPA051239, HPA063663	Approved		Enhanced	Nucleus<br>Vesicles	Renal cancer:1.59e-8 (favourable), Liver cancer:3.41e-5 (unfavourable), Urothelial cancer:5.52e-5 (favourable)	Expressed in all	Tissue enhanced		adipose tissue: 173.3	placenta: 59.2	Cell line enhanced		ASC diff: 131.6;BEWO: 223.4;RT4: 116.1
PPFIBP1	hSGT2, hSgt2p, L2, SGT2	ENSG00000110841	PPFIA binding protein 1	12	27523431-27695564	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA001924	Uncertain		Approved	Plasma membrane<br>Cytosol	Renal cancer:5.11e-7 (favourable), Pancreatic cancer:2.56e-4 (unfavourable), Lung cancer:5.11e-4 (unfavourable), Endometrial cancer:6.29e-4 (unfavourable)	Expressed in all	Expressed in all			ovary: 106.4	Mixed		
PPM1D	PP2C-DELTA, Wip1	ENSG00000170836	Protein phosphatase, Mg2+/Mn2+ dependent 1D	17	60600183-60666280	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA022277	Uncertain		Approved	Endoplasmic reticulum	Colorectal cancer:3.52e-4 (favourable), Liver cancer:4.27e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.6	Expressed in all		
PPP2R1A	PP2A-Aalpha, PP2AA, PR65A	ENSG00000105568	Protein phosphatase 2 scaffold subunit Aalpha	19	52190039-52229533	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB018599			Approved	Cytosol	Renal cancer:1.20e-4 (favourable), Liver cancer:1.76e-4 (unfavourable), Lung cancer:2.50e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 207.6	Expressed in all		
PPP6C	PP6	ENSG00000119414	Protein phosphatase 6 catalytic subunit	9	125146573-125189939	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050940	Uncertain				Renal cancer:4.50e-6 (favourable)	Expressed in all	Expressed in all			thyroid gland: 52.7	Expressed in all		
PRCC	RCCP1	ENSG00000143294	Papillary renal cell carcinoma (translocation-associated)	1	156750610-156800817	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB017151, HPA019463, HPA019481	Supported		Enhanced	Nuclear speckles	Renal cancer:8.99e-15 (unfavourable), Thyroid cancer:3.72e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable), Liver cancer:8.63e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 54.5	Expressed in all		
PRDM1	BLIMP1, PRDI-BF1	ENSG00000057657	PR/SET domain 1	6	106086320-106109939	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030033	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:9.81e-5 (unfavourable)	Expressed in all	Tissue enhanced		esophagus: 61.0	endometrium: 30.1	Cell line enhanced		Karpas-707: 158.5;U-266/70: 62.6;U-266/84: 39.9
PRDM16	KIAA1675, KMT8F, MEL1, MGC166915, PFM13	ENSG00000142611	PR/SET domain 16	1	3069168-3438621	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA050343, HPA060467			Enhanced	Nucleoplasm	Thyroid cancer:4.70e-5 (unfavourable)	Mixed	Mixed			thyroid gland: 7.6	Cell line enhanced		AN3-CA: 1.4;CACO-2: 1.2;HAP1: 1.4;HEK93: 1.6;HHSteC: 1.7;MCF7: 1.2
PREX2	DEP.2, DEPDC2, FLJ12987, P-REX2, PPP1R129	ENSG00000046889	Phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	8	67952118-68237030	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015234, HPA075956	Enhanced		Approved	Endoplasmic reticulum	Renal cancer:1.61e-7 (unfavourable)	Mixed	Mixed			cerebral cortex: 11.9	Cell line enhanced		AF22: 13.9;HUVEC TERT2: 16.1;NTERA-2: 12.2;RH-30: 5.3
PRKACA	PKACa	ENSG00000072062	Protein kinase cAMP-activated catalytic subunit alpha	19	14091688-14118084	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB010361, HPA071185	Approved		Approved	Cytosol	Cervical cancer:6.28e-6 (favourable), Endometrial cancer:6.26e-5 (unfavourable), Pancreatic cancer:6.47e-4 (favourable)	Expressed in all	Expressed in all			heart muscle: 200.4	Expressed in all		
PRKAR1A	CNC1, PRKAR1, TSE1	ENSG00000108946	Protein kinase cAMP-dependent type I regulatory subunit alpha	17	68511780-68551319	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB019378, HPA049979	Approved		Approved	Cytosol		Expressed in all	Expressed in all			parathyroid gland: 564.4	Expressed in all		
PRRX1	PHOX1, PMX1	ENSG00000116132	Paired related homeobox 1	1	170662728-170739419	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA051084, HPA063566	Uncertain		Supported	Nucleoplasm	Renal cancer:6.60e-10 (unfavourable)	Mixed	Mixed			cervix, uterine: 135.8	Cell line enhanced		ASC diff: 240.8;ASC TERT1: 194.6;BJ hTERT+: 165.0;U-138 MG: 137.1;U-2197: 125.0
PSIP1	LEDGF, p52, p75, PSIP2	ENSG00000164985	PC4 and SFRS1 interacting protein 1	9	15464066-15511019	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB013718, HPA019697	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			cerebral cortex: 161.3	Expressed in all		
PTCH1	BCNS, NBCCS, PTCH	ENSG00000185920	Patched 1	9	95442980-95517057	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB013717, HPA075072	Uncertain		Approved	Golgi apparatus		Mixed	Tissue enhanced		cervix, uterine: 41.7	endometrium: 27.2	Cell line enhanced		WM-115: 70.2
PTEN	BZS, MHAM, MMAC1, PTEN1, TEP1	ENSG00000171862	Phosphatase and tensin homolog	10	87863113-87971930	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB004076, HPA031335	Uncertain		Supported	Nucleoplasm<br>Cytosol	Renal cancer:7.35e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 83.6	Expressed in all		
PTK6	BRK	ENSG00000101213	Protein tyrosine kinase 6	20	63528001-63537370	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB032952, HPA036070, HPA036071	Approved		Supported	Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol	Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)	Mixed	Tissue enhanced		esophagus: 61.0;skin: 60.4	duodenum: 29.2	Cell line enhanced		A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
PTPN11	BPTP3, NS1, PTP2C, SH-PTP2, SHP-2, SHP2	ENSG00000179295	Protein tyrosine phosphatase, non-receptor type 11	12	112418351-112509913	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005377	Approved		Supported	Nucleus<br>Nucleoli<br>Actin filaments<br>Cytosol		Expressed in all	Expressed in all			cerebral cortex: 126.0	Expressed in all		
PTPN13	PTP-BAS, PTP-BL, PTP1E, PTPL1	ENSG00000163629	Protein tyrosine phosphatase, non-receptor type 13	4	86594315-86815171	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	CAB002213, HPA048888, HPA065290	Approved		Approved	Plasma membrane<br>Cytosol		Mixed	Mixed			skin: 65.9	Cell line enhanced		AF22: 114.7
PTPRB	PTPB	ENSG00000127329	Protein tyrosine phosphatase, receptor type B	12	70515866-70637440	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB004782, HPA067868	Uncertain		Approved	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable)	Expressed in all	Mixed			lung: 54.0	Cell line enhanced		EFO-21: 22.9;HUVEC TERT2: 51.3;TIME: 74.1
PTPRC	CD45, GP180, LCA, T200	ENSG00000081237	Protein tyrosine phosphatase, receptor type C	1	198638671-198757283	Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000052, HPA000440, CAB002800, CAB056154, CAB068221	Enhanced				Renal cancer:2.42e-4 (unfavourable)	Expressed in all	Expressed in all			lymph node: 372.4	Cell line enhanced		Daudi: 151.8;HEL: 73.7;HL-60: 73.8;MOLT-4: 105.0;U-698: 84.9;U-937: 62.5
PTPRK	R-PTP-kappa	ENSG00000152894	Protein tyrosine phosphatase, receptor type K	6	127968779-128520674	Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054056, HPA054822	Uncertain		Supported	Vesicles<br>Plasma membrane<br>Cell Junctions	Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 27.8	Mixed		
PTPRT	KIAA0283, RPTPrho	ENSG00000196090	Protein tyrosine phosphatase, receptor type T	20	42072752-43189970	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA017336, CAB069423	Approved					Tissue enhanced	Group enriched	5	cerebral cortex: 24.3;fallopian tube: 17.4	placenta: 4.0	Cell line enhanced		BEWO: 1.1
PWWP2A	KIAA1935	ENSG00000170234	PWWP domain containing 2A	5	160061801-160119423	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA046733, HPA058233	Uncertain		Supported	Nucleoplasm<br>Focal adhesion sites	Urothelial cancer:3.51e-4 (favourable), Renal cancer:3.70e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 15.4	Expressed in all		
QKI	QK3	ENSG00000112531	QKI, KH domain containing RNA binding	6	163414000-163578596	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019123, CAB022602	Enhanced	Supported	Supported	Nucleoplasm	Renal cancer:2.31e-5 (unfavourable), Liver cancer:1.27e-4 (unfavourable), Stomach cancer:3.69e-4 (unfavourable)	Tissue enriched	Expressed in all			cerebral cortex: 359.6	Expressed in all		
RABEP1	neurocrescin, RAB5EP, rabaptin-5, RABPT5	ENSG00000029725	Rabaptin, RAB GTPase binding effector protein 1	17	5282265-5385812	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB004549, HPA019669, HPA024235, HPA024691	Enhanced		Enhanced	Vesicles	Pancreatic cancer:6.43e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 88.9	Expressed in all		
RAC1	p21-Rac1, Rac-1, TC-25	ENSG00000136238	Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)	7	6374523-6403977	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB035994, HPA047820	Approved		Approved	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:1.74e-5 (unfavourable), Pancreatic cancer:4.57e-5 (unfavourable), Renal cancer:2.11e-4 (unfavourable), Lung cancer:4.59e-4 (unfavourable)	Expressed in all	Expressed in all			cerebral cortex: 281.6	Expressed in all		
RAD21	hHR21, KIAA0078, SCC1	ENSG00000164754	RAD21 cohesin complex component	8	116845935-116874866	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA020044, CAB022065	Supported		Enhanced	Nucleoplasm	Liver cancer:1.71e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 162.4	Expressed in all		
RAD51B	hREC2, R51H2, RAD51L1, REC2	ENSG00000182185	RAD51 paralog B	14	67819779-68730218	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB016191, HPA051869	Enhanced		Approved	Nucleoplasm<br>Nuclear bodies		Mixed	Mixed			epididymis: 11.0	Expressed in all		
RAF1	c-Raf, CRAF, Raf-1	ENSG00000132155	Raf-1 proto-oncogene, serine/threonine kinase	3	12583601-12664226	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA002640, CAB019291	Approved		Approved	Nuclear speckles		Expressed in all	Expressed in all			parathyroid gland: 100.7	Expressed in all		
RALGDS	RalGEF, RGDS, RGF	ENSG00000160271	Ral guanine nucleotide dissociation stimulator	9	133097720-133149334	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	HPA025961, CAB032582	Approved		Approved	Nucleus	Cervical cancer:4.19e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 52.9	Expressed in all		
RANBP17		ENSG00000204764	RAN binding protein 17	5	170861870-171300015	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters	Evidence at protein level	HPA029568, HPA029569	Uncertain		Approved	Nuclear membrane<br>Nuclear bodies<br>Cytosol		Mixed	Mixed			testis: 2.2	Mixed		
RANBP2	ADANE, ANE1, NUP358	ENSG00000153201	RAN binding protein 2	2	108719481-108785811	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA018437, HPA023960, CAB034063, HPA049497, HPA051675, HPA067564	Supported					Expressed in all	Expressed in all			parathyroid gland: 74.9	Expressed in all		
RAP1GDS1	SmgGDS	ENSG00000138698	Rap1 GTPase-GDP dissociation stimulator 1	4	98261384-98443861	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA019060	Approved		Supported	Cytosol	Renal cancer:2.00e-4 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 93.9	Expressed in all		
RARA	NR1B1, RAR	ENSG00000131759	Retinoic acid receptor alpha	17	40309192-40357643	Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA058282			Supported	Nucleus<br>Cytosol	Endometrial cancer:2.60e-4 (favourable)	Expressed in all	Expressed in all			gallbladder: 68.6	Expressed in all		
RB1	OSRC, PPP1R130, RB	ENSG00000139687	RB transcriptional corepressor 1	13	48303751-48481986	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB000095, CAB016687, HPA050082	Supported		Enhanced	Nucleoplasm	Ovarian cancer:6.92e-4 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 36.1	Mixed		
RBM10	DXS8237E, GPATC9, GPATCH9, KIAA0122, ZRANB5	ENSG00000182872	RNA binding motif protein 10	X	47144869-47186813	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034972, HPA057372	Approved		Enhanced	Nuclear speckles	Pancreatic cancer:2.86e-6 (favourable), Cervical cancer:6.71e-4 (favourable)	Expressed in all	Expressed in all			ovary: 35.1	Expressed in all		
RBM15	OTT, OTT1	ENSG00000162775	RNA binding motif protein 15	1	110338506-110346681	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB015201, HPA019824, HPA049642	Supported		Enhanced	Nucleoplasm	Renal cancer:1.37e-4 (unfavourable), Liver cancer:7.61e-4 (unfavourable), Stomach cancer:7.97e-4 (favourable)	Expressed in all	Mixed			bone marrow: 27.9	Expressed in all		
REL	c-Rel, I-Rel	ENSG00000162924	REL proto-oncogene, NF-kB subunit	2	60881521-60931610	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors	Evidence at protein level	CAB004404	Uncertain					Mixed	Mixed			bone marrow: 29.8	Expressed in all		
RET	CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51	ENSG00000165731	Ret proto-oncogene	10	43077027-43130351	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB002581, HPA008356, HPA008495, CAB018342	Approved	Supported	Supported	Vesicles<br>Plasma membrane<br>Cytosol	Endometrial cancer:5.02e-4 (unfavourable)	Tissue enhanced	Tissue enriched	5	parathyroid gland: 154.5	adrenal gland: 29.8	Cell line enriched	5	SH-SY5Y: 404.3
RHOA	ARH12, ARHA, Rho12, RhoA, RHOH12	ENSG00000067560	Ras homolog family member A	3	49359145-49412998	Cancer-related genes, Predicted intracellular proteins, RAS pathway related proteins	Evidence at protein level	CAB005052	Approved				Renal cancer:3.21e-6 (favourable), Colorectal cancer:3.08e-4 (favourable), Liver cancer:9.15e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 592.0	Expressed in all		
RHOH	ARHH, RhoH, TTF	ENSG00000168421	Ras homolog family member H	4	40191053-40246967	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA030345	Uncertain					Mixed	Tissue enhanced		lymph node: 98.3;tonsil: 77.5	appendix: 47.7	Cell line enhanced		Daudi: 89.6;HMC-1: 81.4;MOLT-4: 142.8;U-266/70: 49.6;U-698: 79.5
RMI2	BLAP18, C16orf75, MGC24665	ENSG00000175643	RecQ mediated genome instability 2	16	11249619-11351762	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA040995	Uncertain		Supported	Nuclear speckles<br>Cytosol	Liver cancer:2.77e-5 (unfavourable), Cervical cancer:5.69e-5 (favourable)	Expressed in all	Mixed			lymph node: 36.9	Expressed in all		
RNF213	C17orf27, KIAA1554, KIAA1618, MYMY2, NET57	ENSG00000173821	Ring finger protein 213	17	80260866-80398786	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA003347, HPA026790	Approved		Supported	Cytosol	Endometrial cancer:4.65e-5 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 65.3	Expressed in all		
RNF43	DKFZp781H0392, FLJ20315, URCC	ENSG00000108375	Ring finger protein 43	17	58352500-58417595	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA008079	Uncertain				Renal cancer:6.04e-9 (favourable)	Tissue enhanced	Mixed			duodenum: 23.4	Cell line enhanced		CACO-2: 20.6;Hep G2: 33.5
ROS1	c-ros-1, MCF3, ROS	ENSG00000047936	ROS proto-oncogene 1, receptor tyrosine kinase	6	117288300-117425855	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA049098, HPA072424	Uncertain		Approved	Vesicles		Tissue enriched	Group enriched	18	epididymis: 70.9;lung: 47.2	seminal vesicle: 3.2	Cell line enhanced		HSkMC: 7.5;hTCEpi: 15.7;LHCN-M2: 12.7
RPL10	DXS648, DXS648E, FLJ23544, L10, NOV, QM	ENSG00000147403	Ribosomal protein L10	X	154389955-154409168	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	CAB010339, HPA011311	Enhanced		Enhanced	Endoplasmic reticulum<br>Cytosol	Renal cancer:7.67e-6 (unfavourable)	Expressed in all	Expressed in all			ovary: 9682.7	Expressed in all		
RPL22	EAP, L22	ENSG00000116251	Ribosomal protein L22	1	6181269-6209389	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA068294			Approved	Nucleus<br>Nucleoli		Expressed in all	Expressed in all			ovary: 1343.4	Expressed in all		
RPL5	L5, PPP1R135	ENSG00000122406	Ribosomal protein L5	1	92832025-92841924	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins	Evidence at protein level	HPA043717, HPA054444	Approved		Supported	Nucleoli<br>Endoplasmic reticulum<br>Cytosol	Renal cancer:6.81e-5 (unfavourable)	Expressed in all	Expressed in all			ovary: 4042.9	Expressed in all		
RPN1	OST1	ENSG00000163902	Ribophorin I	3	128619970-128681075	Cancer-related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB009748, HPA026828, HPA051520	Enhanced		Enhanced	Endoplasmic reticulum	Liver cancer:4.80e-4 (unfavourable)	Expressed in all	Expressed in all			epididymis: 422.3	Expressed in all		
RSPO2	MGC35555	ENSG00000147655	R-spondin 2	8	107899316-108083648	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA024764, CAB025900, HPA053068	Approved					Mixed	Tissue enhanced		cerebral cortex: 20.2;placenta: 25.7	prostate: 15.8	Cell line enhanced		HEK93: 1.7;HEL: 1.6;NTERA-2: 1.0;U-138 MG: 1.8;U-266/70: 4.2
RSPO3	FLJ14440, THSD2	ENSG00000146374	R-spondin 3	6	127118604-127197765	Cancer-related genes, Predicted secreted proteins	Evidence at protein level	HPA029957	Approved					Mixed	Tissue enhanced		endometrium: 103.2;smooth muscle: 102.9	placenta: 73.2	Cell line enhanced		A549: 24.0;U-138 MG: 5.6;U-87 MG: 5.4
RUNX1	AML1, AMLCR1, CBFA2, PEBP2A2	ENSG00000159216	Runt related transcription factor 1	21	34787801-36004667	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004176, HPA037912	Enhanced		Enhanced	Nucleoplasm<br>Vesicles	Renal cancer:3.44e-15 (unfavourable)	Expressed in all	Mixed			breast: 34.0	Cell line enhanced		HEL: 225.2
RUNX1T1	AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2	ENSG00000079102	RUNX1 translocation partner 1	8	91954967-92103286	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049852, HPA070951	Approved		Supported	Nucleoplasm		Mixed	Mixed			cervix, uterine: 12.8	Cell line enhanced		Daudi: 14.0;HEL: 32.2
SALL4	dJ1112F19.1, ZNF797	ENSG00000101115	Spalt like transcription factor 4	20	51782331-51802520	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA015291, HPA015791	Enhanced		Enhanced	Nucleoplasm		Tissue enriched	Group enriched	7	parathyroid gland: 6.7;prostate: 1.4;testis: 5.8;thyroid gland: 3.5	urinary bladder: 0.6	Cell line enhanced		AF22: 24.7;AN3-CA: 16.2;BEWO: 32.0;NTERA-2: 60.1;SiHa: 16.5
SDC4	amphiglycan, ryudocan, SYND4	ENSG00000124145	Syndecan 4	20	45325288-45348424	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA005716, CAB013240	Supported		Approved	Golgi apparatus<br>Plasma membrane	Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable)	Expressed in all	Expressed in all			lung: 250.2	Mixed		
SDHA	FP, SDH2, SDHF	ENSG00000073578	Succinate dehydrogenase complex flavoprotein subunit A	5	218241-256700	Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB034929, HPA041981, HPA064582	Enhanced		Enhanced	Mitochondria	Renal cancer:9.53e-8 (favourable), Breast cancer:6.00e-4 (unfavourable)	Expressed in all	Expressed in all			heart muscle: 248.9	Expressed in all		
SEPT5	H5, HCDCREL-1, PNUTL1	ENSG00000184702	Septin 5	22	19714464-19724772	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB016120, HPA029095, HPA063885	Enhanced		Approved	Nucleoplasm<br>Actin filaments<br>Cytosol	Renal cancer:6.87e-6 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 386.8	Cell line enhanced		K-562: 211.0
SEPT6	KIAA0128, MGC16619, MGC20339, SEP2, SEPT2	ENSG00000125354	Septin 6	X	119615724-119693370	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA003459, HPA005665	Supported		Approved	Cytosol		Expressed in all	Mixed			lymph node: 140.7	Cell line enhanced		MOLT-4: 239.1;REH: 246.9;SH-SY5Y: 417.7
SEPT9	AF17q25, KIAA0991, MSF, MSF1, PNUTL4, SeptD1	ENSG00000184640	Septin 9	17	77280569-77500596	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA042564, HPA050627	Approved		Enhanced	Actin filaments	Liver cancer:1.61e-5 (unfavourable)	Expressed in all	Expressed in all			lymph node: 268.9	Expressed in all		
SET	2PP2A, IPP2A2, PHAPII	ENSG00000119335	SET nuclear proto-oncogene	9	128683424-128696400	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB005232, HPA063683	Supported		Supported	Nucleoplasm<br>Lipid droplets	Liver cancer:9.41e-7 (unfavourable)	Expressed in all	Expressed in all			lymph node: 361.2	Expressed in all		
SETBP1	KIAA0437, SEB	ENSG00000152217	SET binding protein 1	18	44680173-45068510	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA049022, HPA057259	Uncertain		Supported	Nucleus<br>Nuclear bodies<br>Cytosol	Renal cancer:6.34e-8 (favourable)	Mixed	Expressed in all			seminal vesicle: 13.8	Cell line enhanced		AF22: 15.8;Karpas-707: 45.8
SETD2	FLJ23184, HIF-1, HYPB, KIAA1732, KMT3A	ENSG00000181555	SET domain containing 2	3	47016429-47163967	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA042451	Approved		Approved	Nuclear speckles<br>Cytosol	Renal cancer:7.99e-6 (favourable), Melanoma:8.19e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 31.8	Expressed in all		
SF3B1	Hsh155, Prp10, PRPF10, SAP155, SF3b155	ENSG00000115524	Splicing factor 3b subunit 1	2	197389784-197435091	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA050275	Approved		Enhanced	Nuclear speckles		Expressed in all	Expressed in all			endometrium: 348.2	Expressed in all		
SFPQ	PPP1R140, PSF	ENSG00000116560	Splicing factor proline and glutamine rich	1	35176378-35193148	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB009886, HPA047513, HPA054689	Enhanced		Enhanced	Nucleoplasm	Liver cancer:7.91e-13 (unfavourable), Breast cancer:9.56e-5 (favourable)	Expressed in all	Expressed in all			bone marrow: 135.5	Expressed in all		
SFRP4	FRP-4, frpHE	ENSG00000106483	Secreted frizzled related protein 4	7	37905932-38025695	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA009712, HPA050585	Enhanced				Renal cancer:1.36e-5 (unfavourable)	Expressed in all	Group enriched	5	cervix, uterine: 935.5;endometrium: 776.1;fallopian tube: 338.6	smooth muscle: 130.5	Cell line enhanced		ASC diff: 6.5;HSkMC: 2.7;U-937: 2.9
SH2B3	IDDM20, LNK	ENSG00000111252	SH2B adaptor protein 3	12	111405948-111451623	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA005483	Approved		Approved	Nucleoplasm	Renal cancer:6.20e-4 (unfavourable)	Expressed in all	Expressed in all			spleen: 51.1	Cell line enhanced		hTEC/SVTERT24-B: 141.0;U-87 MG: 207.2;WM-115: 163.2
SH3GL1	CNSA1, EEN, MGC111371, SH3D2B, SH3P8	ENSG00000141985	SH3 domain containing GRB2 like 1, endophilin A2	19	4360370-4400547	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021485	Approved		Enhanced	Cytosol	Renal cancer:9.36e-8 (unfavourable), Liver cancer:1.10e-4 (unfavourable), Cervical cancer:1.50e-4 (favourable), Endometrial cancer:1.86e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 114.5	Expressed in all		
SHTN1	KIAA1598, shootin-1, shootin1	ENSG00000187164	Shootin 1	10	116881482-117126586	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037942, HPA037943	Enhanced	Approved	Approved	Nucleus<br>Plasma membrane<br>Cytosol	Urothelial cancer:5.08e-6 (unfavourable), Prostate cancer:5.07e-4 (unfavourable)	Expressed in all	Tissue enhanced		cerebral cortex: 36.1	parathyroid gland: 18.7	Mixed		
SLC34A2	NAPI-3B	ENSG00000157765	Solute carrier family 34 member 2	4	25655301-25678748	Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters	Evidence at protein level	HPA037989	Enhanced					Tissue enhanced	Tissue enriched	10	lung: 1121.1	fallopian tube: 111.8	Group enriched	76	BEWO: 31.0;EFO-21: 114.1;RPTEC TERT1: 66.5
SLC45A3	IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein	ENSG00000158715	Solute carrier family 45 member 3	1	205657851-205680459	Cancer-related genes, Predicted membrane proteins, Transporters	Evidence at protein level	HPA019073, HPA019075	Enhanced		Approved	Nucleoplasm<br>Vesicles	Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable)	Tissue enriched	Tissue enriched	30	prostate: 505.2	stomach: 16.5	Cell line enriched	28	HMC-1: 749.2
SMAD2	JV18-1, MADH2, MADR2	ENSG00000175387	SMAD family member 2	18	47808957-47931146	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors	Evidence at protein level	CAB025507, HPA067203, CAB073546	Approved		Supported	Nucleus<br>Nucleoli<br>Cytosol	Liver cancer:9.44e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 126.7	Expressed in all		
SMAD3	HsT17436, JV15-2, MADH3	ENSG00000166949	SMAD family member 3	15	67063763-67195195	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB008094, HPA046386, HPA067203, CAB069409	Approved		Enhanced	Nucleoplasm<br>Cytosol	Pancreatic cancer:2.48e-4 (unfavourable)	Expressed in all	Expressed in all			esophagus: 54.2	Expressed in all		
SMAD4	DPC4, MADH4	ENSG00000141646	SMAD family member 4	18	51028394-51085045	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019154	Approved		Supported	Nucleoplasm<br>Centrosome<br>Cytosol	Renal cancer:1.92e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 39.3	Expressed in all		
SMARCA4	BAF190, BRG1, FLJ39786, hSNF2b, SNF2, SNF2-BETA, SNF2L4, SNF2LB, SWI2	ENSG00000127616	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	19	10961001-11065395	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004208	Supported		Supported	Nucleoplasm	Liver cancer:1.11e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 39.5	Expressed in all		
SMARCB1	BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5L1, Snr1	ENSG00000099956	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1	22	23786963-23834516	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB009196, HPA018248, HPA019127	Supported		Supported	Nucleoplasm<br>Nucleoli fibrillar center	Renal cancer:1.14e-6 (favourable), Liver cancer:6.52e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 51.2	Expressed in all		
SMARCD1	BAF60A, CRACD1, Rsc6p	ENSG00000066117	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, member 1	12	50084972-50100712	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA004101	Supported		Approved	Nucleoplasm<br>Vesicles	Liver cancer:2.53e-8 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 86.5	Expressed in all		
SMO	FZD11, SMOH	ENSG00000128602	Smoothened, frizzled class receptor	7	129188872-129213545	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011446	Approved					Expressed in all	Mixed			ovary: 30.4	Cell line enhanced		AN3-CA: 84.8;NTERA-2: 69.7
SND1	p100, TDRD11	ENSG00000197157	Staphylococcal nuclease and tudor domain containing 1	7	127652180-128092609	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002529, HPA002632, CAB019323	Enhanced		Enhanced	Cytosol	Endometrial cancer:1.95e-4 (favourable)	Expressed in all	Expressed in all			placenta: 122.3	Expressed in all		
SOCS1	Cish1, JAB, SOCS-1, SSI-1, TIP3	ENSG00000185338	Suppressor of cytokine signaling 1	16	11254405-11256179	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB010355, HPA074108	Approved		Supported	Nucleoplasm<br>Cytoplasmic bodies	Renal cancer:1.08e-6 (unfavourable), Head and neck cancer:1.10e-4 (favourable)	Expressed in all	Tissue enhanced		appendix: 19.3	lymph node: 15.7	Cell line enriched	6	HDLM-2: 102.4
SOX2		ENSG00000181449	SRY-box 2	3	181711924-181714436	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB010648, HPA045725, HPA071379	Approved	Supported	Supported	Nucleoplasm		Tissue enhanced	Tissue enriched	8	cerebral cortex: 117.9	esophagus: 14.8	Cell line enhanced		AF22: 273.3;HAP1: 122.7;NTERA-2: 226.0
SPECC1	CYTSB, FLJ36955, HCMOGT-1, NSP	ENSG00000128487	Sperm antigen with calponin homology and coiled-coil domains 1	17	20009344-20319026	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA021421, HPA021430	Enhanced				Lung cancer:1.06e-5 (unfavourable)	Expressed in all	Expressed in all			testis: 67.2	Cell line enhanced		SiHa: 107.9
SPEN	KIAA0929, MINT, RBM15C, SHARP	ENSG00000065526	Spen family transcriptional repressor	1	15847864-15940460	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA015825, HPA050257	Supported		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			parathyroid gland: 39.0	Expressed in all		
SPOP	BTBD32, TEF2	ENSG00000121067	Speckle type BTB/POZ protein	17	49598884-49678234	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Liver cancer:6.88e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 121.2	Expressed in all		
SRC	ASV, c-src, SRC1	ENSG00000197122	SRC proto-oncogene, non-receptor tyrosine kinase	20	37344685-37406050	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004023, HPA030875	Approved		Enhanced	Plasma membrane<br>Cytosol	Liver cancer:4.90e-5 (unfavourable), Urothelial cancer:5.22e-5 (favourable), Renal cancer:1.22e-4 (unfavourable), Prostate cancer:1.63e-4 (unfavourable)	Expressed in all	Mixed			gallbladder: 43.6	Mixed		
SRGAP3	ARHGAP14, KIAA0411, MEGAP, SRGAP2, WRP	ENSG00000196220	SLIT-ROBO Rho GTPase activating protein 3	3	8980591-9363053	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA036959, HPA044074	Enhanced		Approved	Nucleoplasm		Mixed	Tissue enhanced		cerebral cortex: 26.5;fallopian tube: 17.4	cervix, uterine: 7.9	Cell line enhanced		AF22: 8.9;HBEC3-KT: 5.7;RT4: 8.6;T-47d: 9.6
SRSF2	PR264, SC-35, SC35, SFRS2, SFRS2A	ENSG00000161547	Serine and arginine rich splicing factor 2	17	76734115-76737374	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA049905	Supported		Approved	Nucleus<br>Cytosol	Liver cancer:3.53e-8 (unfavourable), Renal cancer:1.05e-7 (unfavourable), Endometrial cancer:8.73e-4 (unfavourable), Urothelial cancer:9.87e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 127.2	Expressed in all		
SRSF3	SFRS3, SRp20	ENSG00000112081	Serine and arginine rich splicing factor 3	6	36594353-36605600	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB012986, HPA056981	Supported		Supported	Nucleoplasm	Liver cancer:6.22e-5 (unfavourable), Ovarian cancer:1.37e-4 (favourable), Melanoma:1.95e-4 (unfavourable), Renal cancer:2.02e-4 (unfavourable), Colorectal cancer:2.56e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 139.5	Expressed in all		
SS18	SSXT, SYT	ENSG00000141380	SS18, nBAF chromatin remodeling complex subunit	18	26016253-26091217	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA055741, HPA059539	Supported		Approved	Nucleoplasm<br>Cytosol	Renal cancer:4.86e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 75.7	Expressed in all		
SS18L1	CREST, KIAA0693	ENSG00000184402	SS18L1, nBAF chromatin remodeling complex subunit	20	62143795-62182484	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	CAB011827, HPA059046	Approved		Supported	Nucleoplasm<br>Cytosol	Head and neck cancer:8.00e-5 (favourable), Lung cancer:3.74e-4 (favourable)	Expressed in all	Expressed in all			skin: 23.7	Expressed in all		
SSX1	CT5.1	ENSG00000126752	SSX family member 1	X	48255317-48267444	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683	Supported		Approved	Nucleus<br>Nucleoli		Tissue enhanced	Tissue enriched	26	testis: 12.7	epididymis: 0.4	Group enriched	9	Daudi: 47.0;Karpas-707: 66.3;U-2197: 20.0
SSX2	CT5.2a, HD21, HOM-MEL-40, MGC119055, MGC15364, MGC3884, SSX	ENSG00000241476	SSX family member 2	X	52696896-52707189	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA045683, CAB046020	Enhanced		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	113	testis: 46.1	thyroid gland: 0.4	Not detected		
SSX4	CT5.4	ENSG00000268009	SSX family member 4	X	48383516-48393347	Cancer-related genes, Predicted intracellular proteins	Evidence at transcript level	HPA045683	Approved		Approved	Nucleus<br>Nucleoli		Not detected	Tissue enriched	15	testis: 3.8	fallopian tube: 0.2	Group enriched	8	BEWO: 2.1;Karpas-707: 3.9;U-266/70: 2.4;U-266/84: 4.3
STAG2	SA-2, SA2, SCC3B	ENSG00000101972	Stromal antigen 2	X	123960212-124422664	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002857	Supported					Expressed in all	Expressed in all			parathyroid gland: 112.2	Mixed		
STAT3	APRF	ENSG00000168610	Signal transducer and activator of transcription 3	17	42313324-42388568	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001671, CAB003859, HPA058603, CAB068241, CAB068242	Supported		Supported	Nucleoplasm<br>Cytosol		Expressed in all	Expressed in all			gallbladder: 127.5	Mixed		
STAT5B		ENSG00000173757	Signal transducer and activator of transcription 5B	17	42199168-42276707	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB004298, HPA042128, HPA049883, HPA051156	Approved				Renal cancer:2.39e-5 (favourable), Pancreatic cancer:1.63e-4 (favourable), Endometrial cancer:9.37e-4 (favourable)	Expressed in all	Expressed in all			endometrium: 71.3	Cell line enhanced		HDLM-2: 112.6
STAT6	D12S1644, IL-4-STAT	ENSG00000166888	Signal transducer and activator of transcription 6	12	57095408-57132139	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001861	Approved		Enhanced	Nucleoplasm<br>Cytosol	Urothelial cancer:1.14e-4 (favourable), Endometrial cancer:1.69e-4 (favourable), Thyroid cancer:7.76e-4 (favourable)	Expressed in all	Expressed in all			skin: 163.9	Mixed		
STIL	MCPH7, SIL	ENSG00000123473	SCL/TAL1 interrupting locus	1	47250139-47314147	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA046543			Approved	Plasma membrane<br>Cytosol	Pancreatic cancer:1.33e-4 (unfavourable)	Mixed	Mixed			testis: 12.9	Mixed		
STK11	LKB1, PJS	ENSG00000118046	Serine/threonine kinase 11	19	1177558-1228435	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	CAB016231, HPA017254, CAB022105, HPA067481	Approved		Supported	Nucleoplasm<br>Cytosol	Endometrial cancer:3.69e-5 (favourable), Head and neck cancer:1.96e-4 (favourable)	Expressed in all	Expressed in all			testis: 77.1	Mixed		
STRN	PPP2R6A, STRN1	ENSG00000115808	Striatin	2	36843640-36966472	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA017286	Approved		Approved	Nucleoplasm<br>Cytosol	Renal cancer:2.27e-4 (favourable)	Expressed in all	Expressed in all			esophagus: 23.8	Expressed in all		
SUFU	PRO1280, SUFUH, SUFUXL	ENSG00000107882	SUFU negative regulator of hedgehog signaling	10	102503987-102633535	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA008700	Enhanced		Supported	Nucleus		Expressed in all	Mixed			parathyroid gland: 16.1	Expressed in all		
SUZ12	CHET9, JJAZ1, KIAA0160	ENSG00000178691	SUZ12 polycomb repressive complex 2 subunit	17	31937018-32001045	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA057436	Approved		Approved	Nucleus<br>Nucleoli<br>Nuclear bodies		Expressed in all	Expressed in all			testis: 50.7	Expressed in all		
SYK		ENSG00000165025	Spleen associated tyrosine kinase	9	90801787-90898549	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA001384, CAB007773	Enhanced		Approved	Vesicles<br>Plasma membrane<br>Cytosol		Expressed in all	Mixed			parathyroid gland: 96.0	Cell line enhanced		Daudi: 89.3;HEL: 64.8;HL-60: 80.0;REH: 76.3
TAF15	hTAFII68, Npl3, RBP56, TAF2N	ENSG00000270647	TATA-box binding protein associated factor 15	17	35713791-35864615	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA052059, HPA063647	Enhanced		Enhanced	Nucleoplasm		Expressed in all	Expressed in all			lymph node: 61.1	Expressed in all		
TAL1	bHLHa17, SCL, TCL5	ENSG00000162367	TAL bHLH transcription factor 1, erythroid differentiation factor	1	47216290-47232220	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB017805, HPA047866, HPA073983	Approved		Supported	Nucleus		Mixed	Tissue enhanced		bone marrow: 17.7	placenta: 10.0	Cell line enhanced		HEL: 137.6;HMC-1: 62.0;K-562: 43.6;TIME: 28.0
TAL2	bHLHa19	ENSG00000186051	TAL bHLH transcription factor 2	9	105662457-105663112	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030886	Uncertain		Approved	Cytosol	Renal cancer:2.69e-4 (favourable)	Tissue enhanced	Group enriched	5	kidney: 3.5;skeletal muscle: 4.8	epididymis: 0.8	Cell line enhanced		HAP1: 3.1;K-562: 7.5
TBL1XR1	C21, DC42, FLJ12894, IRA1, TBLR1	ENSG00000177565	Transducin beta like 1 X-linked receptor 1	3	177019340-177228000	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA019182	Supported		Approved	Nucleoplasm	Liver cancer:1.08e-7 (unfavourable), Renal cancer:4.25e-5 (unfavourable), Glioma:7.23e-5 (favourable)	Expressed in all	Expressed in all			thyroid gland: 59.4	Expressed in all		
TBX3	TBX3-ISO, UMS, XHL	ENSG00000135111	T-box 3	12	114670254-114684164	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA005799			Approved	Nucleoplasm<br>Cytosol	Urothelial cancer:3.28e-4 (favourable)	Expressed in all	Tissue enhanced		adrenal gland: 200.0	prostate: 119.8	Cell line enhanced		BJ: 87.5;BJ hTERT+: 80.2;RT4: 103.3
TCEA1	GTF2S, SII, TCEA, TF2S, TFIIS	ENSG00000187735	Transcription elongation factor A1	8	53966552-54022529	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA043786	Approved		Supported	Nucleus<br>Nucleoli	Renal cancer:3.75e-5 (unfavourable)	Expressed in all	Expressed in all			thyroid gland: 199.9	Expressed in all		
TCF12	bHLHb20, HEB, HsT17266, HTF4	ENSG00000140262	Transcription factor 12	15	56918623-57299281	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors	Evidence at protein level	CAB004432, HPA065827	Approved		Supported	Nucleoplasm<br>Nuclear speckles	Renal cancer:5.24e-5 (unfavourable), Melanoma:8.89e-4 (unfavourable)	Expressed in all	Expressed in all			cervix, uterine: 116.2	Expressed in all		
TCF3	bHLHb21, E2A, E47, ITF1, MGC129647, MGC129648, VDIR	ENSG00000071564	Transcription factor 3	19	1609290-1652605	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB018351, HPA049808, HPA062476	Approved		Enhanced	Nucleoplasm	Renal cancer:1.53e-4 (unfavourable), Liver cancer:2.46e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 103.3	Expressed in all		
TCF7L2	TCF-4, TCF4	ENSG00000148737	Transcription factor 7 like 2	10	112950250-113167678	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB013535, HPA038800	Supported	Approved	Supported	Nucleoplasm<br>Nuclear bodies		Expressed in all	Expressed in all			endometrium: 30.9	Mixed		
TCL1A	TCL1	ENSG00000100721	T-cell leukemia/lymphoma 1A	14	95709967-95714196	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB004045, HPA016604	Enhanced					Tissue enriched	Tissue enhanced		lymph node: 324.7;tonsil: 196.7	spleen: 77.8	Group enriched	147	Daudi: 334.2;REH: 557.7;U-698: 425.7
TERT	EST2, hEST2, TCS1, TP2, TRT	ENSG00000164362	Telomerase reverse transcriptase	5	1253147-1295069	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins	Evidence at protein level	HPA054641, HPA065897	Supported		Enhanced	Nucleoplasm<br>Nuclear speckles<br>Cytosol		Mixed	Not detected			lymph node,testis: 0.5	Cell line enhanced		ASC TERT1: 349.5;fHDF/TERT166: 388.9;HBEC3-KT: 725.5;hTEC/SVTERT24-B: 626.8;TIME: 672.9
TET1	bA119F7.1, CXXC6, KIAA1676, LCX	ENSG00000138336	Tet methylcytosine dioxygenase 1	10	68560656-68694482	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA019032, HPA057273			Supported	Nucleus<br>Nuclear membrane		Tissue enriched	Mixed			parathyroid gland: 2.4	Cell line enhanced		BEWO: 17.6;HAP1: 21.7;K-562: 11.0;NTERA-2: 12.2
TET2	FLJ20032, KIAA1546	ENSG00000168769	Tet methylcytosine dioxygenase 2	4	105145875-105279816	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA043135	Supported		Approved	Nucleoplasm		Mixed	Mixed			bone marrow: 15.7	Mixed		
TFE3	bHLHe33, TFEA	ENSG00000068323	Transcription factor binding to IGHM enhancer 3	X	49028726-49043486	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023881	Approved		Supported	Nucleoplasm<br>Cytosol	Renal cancer:2.19e-8 (unfavourable), Liver cancer:6.03e-5 (unfavourable)	Expressed in all	Expressed in all			seminal vesicle: 24.4	Expressed in all		
TFEB	bHLHe35, TCFEB	ENSG00000112561	Transcription factor EB	6	41683978-41736259	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA049532			Supported	Nucleoplasm	Renal cancer:1.06e-5 (favourable), Pancreatic cancer:4.77e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 54.3	Cell line enhanced		BEWO: 65.1;U-698: 44.9
TFG	FLJ36137, SPG57, TF6	ENSG00000114354	TRK-fused gene	3	100709331-100748966	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA019473, HPA052206	Approved		Approved	Vesicles<br>Cytosol	Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 164.5	Expressed in all		
TFPT	amida, FB1, INO80F	ENSG00000105619	TCF3 fusion partner	19	54107013-54115675	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA034958, HPA058534	Approved		Supported	Nucleoplasm<br>Nuclear membrane	Pancreatic cancer:3.13e-4 (favourable), Colorectal cancer:5.13e-4 (unfavourable), Liver cancer:5.25e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 10.6	Mixed		
TFRC	CD71, p90, TFR1	ENSG00000072274	Transferrin receptor	3	196027183-196082189	Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB000153, HPA028598	Enhanced		Supported	Endosomes<br>Lysosomes	Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 157.4	Expressed in all		
TGFBR2	MFS2	ENSG00000163513	Transforming growth factor beta receptor 2	3	30606502-30694142	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins	Evidence at protein level	CAB073537			Supported	Plasma membrane		Expressed in all	Expressed in all			adipose tissue: 292.3	Cell line enhanced		ASC TERT1: 366.2;LHCN-M2: 371.8;TIME: 336.9
THRAP3	TRAP150	ENSG00000054118	Thyroid hormone receptor associated protein 3	1	36224416-36305357	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA012041, CAB017472, HPA063765	Supported		Enhanced	Nuclear speckles	Stomach cancer:5.36e-4 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 99.0	Expressed in all		
TLX1	HOX11, TCL3	ENSG00000107807	T-cell leukemia homeobox 1	10	101130505-101137789	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level						Colorectal cancer:7.32e-4 (unfavourable)	Mixed	Tissue enriched	5	spleen: 31.3	salivary gland: 6.0	Cell line enhanced		HAP1: 4.1;K-562: 10.7;SH-SY5Y: 2.9
TLX3	HOX11L2, RNX	ENSG00000164438	T-cell leukemia homeobox 3	5	171309284-171312134	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA030504, HPA060957, HPA069359	Approved		Supported	Nucleoplasm		Tissue enhanced	Not detected			all non-specific tissues: 0.0	Cell line enriched	6	SH-SY5Y: 28.2
TMPRSS2	PRSS10	ENSG00000184012	Transmembrane protease, serine 2	21	41464551-41531116	Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA034493, HPA035787	Enhanced		Supported	Nucleoplasm<br>Cell Junctions	Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable)	Tissue enriched	Tissue enhanced		prostate: 489.3	stomach: 142.6	Cell line enhanced		CACO-2: 21.8;RT4: 50.4;SK-BR-3: 9.5
TNFAIP3	A20, OTUD7C	ENSG00000118503	TNF alpha induced protein 3	6	137867188-137883312	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA002116, HPA067479	Approved		Supported	Vesicles	Renal cancer:6.05e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 345.2	Cell line enhanced		Karpas-707: 118.8;REH: 135.9
TNFRSF14	ATAR, CD270, HVEA, HVEM, LIGHTR, TR2	ENSG00000157873	TNF receptor superfamily member 14	1	2555639-2565382	Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	HPA006404, CAB026150, CAB030007	Approved		Approved	Cytosol<br>Rods & Rings	Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable)	Expressed in all	Expressed in all			duodenum: 45.5	Cell line enhanced		CAPAN-2: 23.4;HDLM-2: 25.7;HHSteC: 25.4;SK-MEL-30: 41.0
TNFRSF17	BCM, BCMA, CD269, TNFRSF13A	ENSG00000048462	TNF receptor superfamily member 17	16	11965107-11968068	Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level						Head and neck cancer:1.58e-6 (favourable), Breast cancer:1.35e-5 (favourable)	Mixed	Tissue enhanced		tonsil: 36.7	lymph node: 30.8	Group enriched	7	Karpas-707: 114.0;RPMI-8226: 179.8;U-266/70: 561.8;U-266/84: 274.9
TOP1		ENSG00000198900	Topoisomerase (DNA) I	20	41028818-41124487	Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins	Evidence at protein level	CAB009058, HPA019039	Enhanced		Supported	Nucleus<br>Nucleoli fibrillar center	Liver cancer:6.42e-4 (unfavourable)	Expressed in all	Expressed in all			placenta: 71.7	Expressed in all		
TP53	LFS1, p53	ENSG00000141510	Tumor protein p53	17	7661779-7687550	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters	Evidence at protein level	CAB002973, CAB039238, CAB039239, HPA051244, CAB072876	Enhanced		Enhanced	Nucleoplasm	Endometrial cancer:1.35e-4 (favourable), Prostate cancer:5.01e-4 (unfavourable)	Expressed in all	Expressed in all			fallopian tube: 50.3	Expressed in all		
TP63	EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L	ENSG00000073282	Tumor protein p63	3	189631416-189897279	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000083, HPA006288, HPA007010	Enhanced		Enhanced	Nucleoplasm<br>Golgi apparatus<br>Cytosol	Breast cancer:1.07e-4 (favourable)	Group enriched	Tissue enhanced		esophagus: 60.9;skin: 164.1	urinary bladder: 28.8	Group enriched	5	HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
TPM3	NEM1, TRK	ENSG00000143549	Tropomyosin 3	1	154155304-154194648	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA000261, HPA009066, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Liver cancer:6.73e-6 (unfavourable), Ovarian cancer:2.39e-5 (favourable), Renal cancer:3.12e-5 (unfavourable), Pancreatic cancer:3.65e-4 (unfavourable), Lung cancer:4.01e-4 (unfavourable)	Expressed in all	Tissue enriched	7	skeletal muscle: 2869.3	bone marrow: 428.4	Expressed in all		
TPM4		ENSG00000167460	Tropomyosin 4	19	16067021-16103005	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	CAB004685, HPA047089, HPA053624	Approved		Approved	Actin filaments<br>Cytosol	Renal cancer:1.26e-10 (unfavourable), Pancreatic cancer:3.07e-4 (unfavourable)	Expressed in all	Expressed in all			smooth muscle: 814.8	Expressed in all		
TPR		ENSG00000047410	Translocated promoter region, nuclear basket protein	1	186311652-186375693	Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Transporters	Evidence at protein level	HPA019661, HPA019663, HPA024336	Enhanced		Enhanced	Nuclear membrane	Liver cancer:1.06e-4 (unfavourable), Head and neck cancer:4.71e-4 (favourable)	Expressed in all	Expressed in all			testis: 79.0	Expressed in all		
TRAF7	DKFZp586I021, MGC7807, RFWD1, RNF119	ENSG00000131653	TNF receptor associated factor 7	16	2155698-2178129	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA041229	Approved		Supported	Vesicles<br>Plasma membrane		Expressed in all	Expressed in all			skin: 40.6	Expressed in all		
TRIM24	hTIF1, RNF82, TIF1, Tif1a	ENSG00000122779	Tripartite motif containing 24	7	138460334-138589993	Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins	Evidence at protein level	HPA043495, HPA061717	Approved		Enhanced	Nucleoplasm	Lung cancer:6.57e-4 (favourable), Liver cancer:9.94e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 49.6	Expressed in all		
TRIM27	RFP, RNF76	ENSG00000204713	Tripartite motif containing 27	6	28903002-28923989	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA048684, HPA053408	Approved		Approved	Nucleus<br>Nucleoli	Renal cancer:3.50e-6 (unfavourable), Urothelial cancer:2.71e-4 (favourable)	Expressed in all	Mixed			appendix: 5.6	Mixed		
TRIM33	FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA	ENSG00000197323	Tripartite motif containing 33	1	114392777-114511160	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA004345	Supported		Approved	Nucleoplasm<br>Vesicles	Colorectal cancer:6.20e-4 (favourable), Head and neck cancer:8.93e-4 (favourable)	Expressed in all	Expressed in all			testis: 46.2	Expressed in all		
TRIP11	CEV14, GMAP-210, GMAP210, Trip230	ENSG00000100815	Thyroid hormone receptor interactor 11	14	91965991-92040896	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA002570, HPA070684	Supported		Enhanced	Nucleus<br>Golgi apparatus	Renal cancer:1.78e-6 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 38.5	Expressed in all		
TRRAP	PAF400, TR-AP, Tra1	ENSG00000196367	Transformation/transcription domain associated protein	7	98877933-99013243	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054376			Supported	Nucleoplasm<br>Golgi apparatus	Liver cancer:8.77e-4 (unfavourable)	Expressed in all	Expressed in all			parathyroid gland: 22.6	Expressed in all		
TSC1	hamartin, KIAA0243, LAM, TSC	ENSG00000165699	Tuberous sclerosis 1	9	132891348-132944633	Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins	Evidence at protein level	CAB011568, CAB012481, HPA074132	Supported		Enhanced	Cytosol	Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable)	Expressed in all	Expressed in all			testis: 33.7	Expressed in all		
TSC2	LAM, PPP1R160, TSC4, tuberin	ENSG00000103197	Tuberous sclerosis 2	16	2047465-2088720	Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	CAB002225, HPA030409, HPA049679	Approved		Enhanced	Cytosol	Pancreatic cancer:5.06e-4 (favourable)	Expressed in all	Expressed in all			seminal vesicle: 36.7	Expressed in all		
TSHR	LGR3	ENSG00000165409	Thyroid stimulating hormone receptor	14	80954989-81146302	Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins	Evidence at protein level	CAB000473	Approved					Tissue enriched	Tissue enriched	282	thyroid gland: 445.5	lymph node: 1.5	Cell line enhanced		MOLT-4: 18.4;SCLC-21H: 25.2;U-266/70: 7.9
TTL	MGC46235	ENSG00000114999	Tubulin tyrosine ligase	2	112482154-112541739	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA066819			Approved	Nucleoplasm<br>Vesicles	Liver cancer:5.65e-4 (unfavourable)	Expressed in all	Mixed			cerebral cortex: 4.4	Mixed		
U2AF1	RN, RNU2AF1, U2AF35, U2AFBP	ENSG00000160201	U2 small nuclear RNA auxiliary factor 1	21	43092956-43107587	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA044833, HPA052083	Supported		Enhanced	Nucleoplasm		Not detected	Expressed in all			thyroid gland: 70.1	Expressed in all		
UBR5	DD5, EDD, EDD1, HYD, KIAA0896	ENSG00000104517	Ubiquitin protein ligase E3 component n-recognin 5	8	102253012-102412841	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA053688			Supported	Nucleoplasm<br>Cytosol	Liver cancer:1.26e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 80.2	Expressed in all		
USP6	HRP1, Tre-2, TRE17, Tre2, TRESMCR	ENSG00000129204	Ubiquitin specific peptidase 6	17	5116438-5175034	Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins	Evidence at protein level	HPA046969			Uncertain	Vesicles		Tissue enriched	Group enriched	5	ovary: 3.5;skeletal muscle: 7.5;testis: 17.1	smooth muscle: 1.8	Mixed		
USP8	HumORF8, KIAA0055, SPG59, UBPY	ENSG00000138592	Ubiquitin specific peptidase 8	15	50424380-50514419	Cancer-related genes, Enzymes, Predicted intracellular proteins	Evidence at protein level	HPA050215	Approved		Supported	Golgi apparatus<br>Cytosol	Renal cancer:1.29e-5 (favourable)	Expressed in all	Expressed in all			parathyroid gland: 77.0	Expressed in all		
VHL	VHL1	ENSG00000134086	Von Hippel-Lindau tumor suppressor	3	10141008-10152220	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	CAB005430, HPA031631, HPA031632	Uncertain		Enhanced	Nucleoplasm<br>Cytosol	Liver cancer:1.32e-5 (unfavourable), Breast cancer:9.02e-5 (unfavourable), Stomach cancer:7.84e-4 (favourable)	Expressed in all	Expressed in all			lymph node: 34.7	Expressed in all		
VTI1A	MVti1, Vti1-rp2, Vti1a	ENSG00000151532	Vesicle transport through interaction with t-SNAREs 1A	10	112446998-112818744	Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins	Evidence at protein level	HPA054108	Supported		Supported	Golgi apparatus<br>Vesicles	Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable)	Expressed in all	Mixed			parathyroid gland: 12.1	Expressed in all		
WDCP	C2orf44, FLJ21945	ENSG00000163026	WD repeat and coiled coil containing	2	24029340-24049575	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA041054	Approved		Approved	Nucleoli<br>Cytosol	Liver cancer:5.14e-8 (unfavourable), Endometrial cancer:6.53e-4 (unfavourable)	Expressed in all	Mixed			testis: 9.3	Expressed in all		
WIF1		ENSG00000156076	WNT inhibitory factor 1	12	65050626-65121566	Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins	Evidence at protein level	HPA039104	Approved					Tissue enhanced	Tissue enriched	6	lung: 159.4	cerebral cortex: 26.4	Cell line enhanced		HEK93: 1.9;NTERA-2: 2.7
WT1	AWT1, GUD, NPHS4, WAGR, WIT-2	ENSG00000184937	Wilms tumor 1	11	32387775-32435630	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	CAB000327, HPA035717, HPA053848	Enhanced		Supported	Nucleoplasm		Tissue enriched	Tissue enhanced		endometrium: 112.9;fallopian tube: 126.5;smooth muscle: 80.2	testis: 55.1	Cell line enhanced		HEL: 23.8;HMC-1: 28.7;K-562: 21.7;NB-4: 40.6;THP-1: 20.5
WWTR1	DKFZp586I1419, TAZ	ENSG00000018408	WW domain containing transcription regulator 1	3	149517235-149736714	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA007415, CAB017483, CAB068248	Enhanced		Enhanced	Nucleoplasm<br>Nuclear bodies<br>Cytosol		Expressed in all	Mixed			endometrium: 71.0	Cell line enhanced		EFO-21: 230.5
XPO1	CRM1, emb	ENSG00000082898	Exportin 1	2	61477849-61538626	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters	Evidence at protein level	CAB010184, HPA042933	Supported		Enhanced	Nucleoplasm<br>Nuclear membrane<br>Vesicles<br>Cytosol	Liver cancer:1.84e-5 (unfavourable), Renal cancer:3.74e-4 (unfavourable)	Expressed in all	Expressed in all			testis: 139.1	Expressed in all		
YWHAE	FLJ45465	ENSG00000108953	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	17	1344272-1400378	Cancer-related genes, Plasma proteins, Predicted intracellular proteins	Evidence at protein level	HPA008445, CAB016200, CAB021109, CAB047350	Approved		Uncertain	Cytosol	Endometrial cancer:6.48e-6 (favourable)	Expressed in all	Expressed in all			cerebral cortex: 451.5	Expressed in all		
ZBTB16	PLZF, ZNF145	ENSG00000109906	Zinc finger and BTB domain containing 16	11	114059593-114250676	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA001499, CAB004540	Uncertain				Renal cancer:2.21e-4 (favourable)	Tissue enhanced	Mixed			ovary: 59.5	Cell line enhanced		ASC diff: 40.2;ASC TERT1: 23.6;HEL: 33.4;HHSteC: 21.2;HSkMC: 19.6;hTCEpi: 18.6;hTERT-HME1: 17.2
ZCCHC8	DKFZp434E2220	ENSG00000033030	Zinc finger CCHC-type containing 8	12	122471600-122501073	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level	HPA037483, HPA037484	Supported		Enhanced	Nucleoplasm<br>Nuclear bodies	Renal cancer:5.36e-4 (unfavourable), Melanoma:7.40e-4 (unfavourable)	Expressed in all	Expressed in all			bone marrow: 33.1	Expressed in all		
ZFHX3	ATBF1, ZNF927	ENSG00000140836	Zinc finger homeobox 3	16	72782885-73059698	Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA059353	Uncertain				Renal cancer:1.37e-5 (favourable), Breast cancer:1.55e-4 (unfavourable)	Expressed in all	Tissue enhanced		parathyroid gland: 28.3	thyroid gland: 12.4	Mixed		
ZMYM2	FIM, MYM, RAMP, ZNF198	ENSG00000121741	Zinc finger MYM-type containing 2	13	19958670-20091829	Cancer-related genes, Disease related genes, Predicted intracellular proteins	Evidence at protein level	HPA031765	Approved		Approved	Nucleoplasm<br>Endoplasmic reticulum	Urothelial cancer:6.07e-4 (favourable)	Expressed in all	Expressed in all			testis: 88.0	Expressed in all		
ZNF331	RITA, ZNF361, ZNF463	ENSG00000130844	Zinc finger protein 331	19	53520981-53580269	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA063157			Approved	Nucleoplasm	Stomach cancer:4.79e-4 (unfavourable), Thyroid cancer:7.43e-4 (unfavourable)	Expressed in all	Expressed in all			adrenal gland: 208.6	Cell line enhanced		HEK93: 73.6
ZNF384	CAGH1A, CIZ, NMP4, NP, TNRC1	ENSG00000126746	Zinc finger protein 384	12	6666477-6689572	Cancer-related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA004051	Supported		Supported	Nucleoplasm		Expressed in all	Expressed in all			endometrium: 66.0	Expressed in all		
ZNF521	EHZF, Evi3	ENSG00000198795	Zinc finger protein 521	18	25061926-25352190	Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors	Evidence at protein level	HPA023056, HPA023849	Enhanced		Approved	Nucleoplasm		Mixed	Mixed			spleen: 29.0	Cell line enhanced		AF22: 66.8;HUVEC TERT2: 39.1
ZRSR2	U2AF1-RS2, U2AF1L2, URP, ZC3H22	ENSG00000169249	Zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2	X	15790472-15823260	Cancer-related genes, Predicted intracellular proteins	Evidence at protein level						Renal cancer:4.87e-5 (unfavourable), Endometrial cancer:8.50e-5 (favourable), Urothelial cancer:2.97e-4 (favourable), Breast cancer:7.96e-4 (favourable)	Expressed in all	Expressed in all			spleen: 34.1	Expressed in all		
